{"content":"<li class=\"n-box-item date-title\" data-end=\"1573793999\" data-start=\"1573707600\" data-txt=\"Monday, December 23, 2019\">Thursday, November 14, 2019</li><li class=\"n-box-item sa-box-item\" data-id=\"3519635\" data-ts=\"1573778607\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OXY\" target=\"_blank\">OXY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3519635-court-rejects-icahn-lawsuit-seeking-occidental-takeover-records\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Court rejects Icahn lawsuit seeking Occidental takeover records</a></h4><ul><li><a href=\"https://www.reuters.com/article/us-occidental-icahn-lawsuit/court-tosses-carl-icahns-lawsuit-seeking-occidental-acquisition-records-idUSKBN1XO328\" target=\"_blank\">Carl Icahn will not have access</a> to Occidental Petroleum's (NYSE:<a href='https://seekingalpha.com/symbol/OXY' title='Occidental Petroleum Corporation'>OXY</a>) Anadarko acquisition records to support his proxy fight against the company's board, a Delaware court judge ruled today.</li><li>Icahn sued OXY to try to obtain financial records and details of the company's negotiations with Anadarko, but the judge found Icahn's complaints about OXY's mismanagement were \"nothing more than disagreements\" with the company's directors and his  lawsuit failed to show how the documents would advance his proxy  contest; Icahn plans to appeal the ruling.</li><li>Separately, Berkshire Hathaway (<a href='https://seekingalpha.com/symbol/BRK.A' title='Berkshire Hathaway Inc.'>BRK.A</a>, <a href='https://seekingalpha.com/symbol/BRK.B' title='Berkshire Hathaway Inc.'>BRK.B</a>) <a href=\"https://www.sec.gov/Archives/edgar/data/1067983/000095012319011362/xslForm13F_X01/primary_doc.xml\" target=\"_blank\">disclosed a new stake in OXY</a>, worth ~$332M.</li><li>OXY <font color=\"green\">+2.2%</font> after-hours.</li></ul><div class=\"tiny-share-widget\" data-id=\"3519635\" data-linked=\"Court rejects Icahn lawsuit seeking Occidental takeover records\" data-tweet=\"$OXY $BRK.A $BRK.B - Court rejects Icahn lawsuit seeking Occidental takeover records https://seekingalpha.com/news/3519635-court-rejects-icahn-lawsuit-seeking-occidental-takeover-records?source=tweet\" data-url=\"https://seekingalpha.com/news/3519635-court-rejects-icahn-lawsuit-seeking-occidental-takeover-records\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:43 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>32&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3519633\" data-ts=\"1573777638\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ACB\" target=\"_blank\">ACB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3519633-aurora-cannabis-follows-canopy-big-q3-dropoff\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Aurora Cannabis follows Canopy with big Q3 dropoff</a></h4><ul><li>Aurora Cannabis (NYSE:<a href='https://seekingalpha.com/symbol/ACB' title='Aurora Cannabis Inc.'>ACB</a>) <font color=\"red\">-12.7%</font> after-hours as <a href=\"https://seekingalpha.com/news/3519583-aurora-cannabis-eps-beats-c-0_06-misses-revenue\" target=\"_blank\">Q3 results</a> show a 24% Q/Q drop in revenues to C$75.3M (US$56.8M) from C$98.9M, and the company said it would <a href=\"https://www.marketwatch.com/story/aurora-stock-plunges-9-as-cannabis-producer-scales-back-expansion-amid-declining-revenue-2019-11-14\" target=\"_blank\">slow its expansion plans</a> in Canada and abroad.</li><li>ACB's Q3 adjusted EBITDA loss was $39.7M, <a href=\"https://www.bnnbloomberg.ca/aurora-becomes-latest-pot-firm-to-miss-estimates-1.1348265\" target=\"_blank\">wider than the expected</a> $20.8M loss.</li><li>ACB said recreational cannabis orders from the provinces \"slowed considerably\" in the summer, citing the \"slow pace\" of getting pot shops licensed and running.</li><li>The company plans to immediately stop construction at its Aurora Nordic 2 weed-growing facility in Denmark, saving ~C$80M over the next 12 months, and delay the final construction and activation of its Aurora Sun facility in Canada.</li><li>ACB also said it reached an agreement with investors holding $155M of its March 2020 convertible debentures to convert early at a  lower price.</li><li>Shares closed <font color=\"red\">-7.3%</font> in regular trade after Canopy Growth (NYSE:<a href='https://seekingalpha.com/symbol/CGC' title='Canopy Growth Corporation'>CGC</a>) reported a 15% Q/Q drop in net revenue; CGC <font color=\"red\">-2.1%</font> after-hours following a 14.4% decline in regular trade.</li></ul><div class=\"tiny-share-widget\" data-id=\"3519633\" data-linked=\"Aurora Cannabis follows Canopy with big Q3 dropoff\" data-tweet=\"$ACB $CGC - Aurora Cannabis follows Canopy with big Q3 dropoff https://seekingalpha.com/news/3519633-aurora-cannabis-follows-canopy-big-q3-dropoff?source=tweet\" data-url=\"https://seekingalpha.com/news/3519633-aurora-cannabis-follows-canopy-big-q3-dropoff\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:27 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>87&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3519630\" data-ts=\"1573775503\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3519630-strong-october-for-videogames-despite-drop-from-record\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Strong October for videogames despite drop from record</a></h4><ul>    <li>Videogame sales overall dropped off again year over year in October, but against the toughest comparison.</li>    <li>Sales fell 34% overall, to $1.03B, according to NPD Group. But October 2019 was the second-best October this decade, trailing only <a href=\"https://seekingalpha.com/news/3411488-key-october-releases-pace-videogame-sales-record\" target=\"_blank\">last October's record-setting $1.57B</a>, the firm says.</li>    <li>That's due to the now-typical drop in hardware as this console generation ages, along with fewer blockbuster software releases this go-round. Hardware sales fell 41% to $182M; software sales dropped 37% to $620M; and accessories/game card sales dropped 16% to $231M.</li>    <li>Year to date, overall spending is off 10% from last year.</li>    <li>Nintendo Switch (<a href='https://seekingalpha.com/symbol/NTDOY' title='Nintendo Co., Ltd.'>OTCPK:NTDOY</a>) is again the only hardware platform with gains for October or for year-to-date; it's still the best-selling platform for 2019 vs. the older Xbox One (NASDAQ:<a href='https://seekingalpha.com/symbol/MSFT' title='Microsoft Corporation'>MSFT</a>) and PlayStation 4 (NYSE:<a href='https://seekingalpha.com/symbol/SNE' title='Sony Corporation'>SNE</a>).</li>    <li><i>Call of Duty: Modern Warfare</i> (NASDAQ:<a href='https://seekingalpha.com/symbol/ATVI' title='Activision Blizzard, Inc.'>ATVI</a>) debuted atop the software dollar sales chart, outperforming <i>The Outer Worlds</i> (NASDAQ:<a href='https://seekingalpha.com/symbol/TTWO' title='Take-Two Interactive Software, Inc.'>TTWO</a>) and <i>Luigi's Mansion 3</i> (<a href='https://seekingalpha.com/symbol/NTDOY' title='Nintendo Co., Ltd.'>OTCPK:NTDOY</a>). The new <i>CoD</i> also becomes 2019's best-selling game.</li>    <li>Rounding out the software top 10: No. 4, <i>Madden NFL 20</i> (NASDAQ:<a href='https://seekingalpha.com/symbol/EA' title='Electronic Arts Inc.'>EA</a>); No. 5, <i>NBA 2K20</i> (<a href='https://seekingalpha.com/symbol/TTWO' title='Take-Two Interactive Software, Inc.'>TTWO</a>); No. 6, <i>Tom Clancy's Ghost Recon Breakpoint</i> (<a href='https://seekingalpha.com/symbol/UBSFY' title='Ubisoft Entertainment SA'>OTCPK:UBSFY</a>); No. 7, <i>WWE 2K20</i> (<a href='https://seekingalpha.com/symbol/TTWO' title='Take-Two Interactive Software, Inc.'>TTWO</a>); No. 8, <i>FIFA 20</i> (<a href='https://seekingalpha.com/symbol/EA' title='Electronic Arts Inc.'>EA</a>); No. 9, <i>Borderlands 3</i> (<a href='https://seekingalpha.com/symbol/TTWO' title='Take-Two Interactive Software, Inc.'>TTWO</a>); No. 10, <i>Ring Fit Adventure</i> (<a href='https://seekingalpha.com/symbol/NTDOY' title='Nintendo Co., Ltd.'>OTCPK:NTDOY</a>).</li>    <li>Related tickers with after-hours moves: <a href='https://seekingalpha.com/symbol/NTDOY' title='Nintendo Co., Ltd.'>OTCPK:NTDOY</a>, <a href='https://seekingalpha.com/symbol/SNE' title='Sony Corporation'>SNE</a> flat, <a href='https://seekingalpha.com/symbol/MSFT' title='Microsoft Corporation'>MSFT</a> flat, <a href='https://seekingalpha.com/symbol/EA' title='Electronic Arts Inc.'>EA</a> flat, <a href='https://seekingalpha.com/symbol/ATVI' title='Activision Blizzard, Inc.'>ATVI</a> <font color=\"red\">-0.8%</font>, <a href='https://seekingalpha.com/symbol/TTWO' title='Take-Two Interactive Software, Inc.'>TTWO</a> flat, <a href='https://seekingalpha.com/symbol/T' title='AT&T Inc.'>T</a> <font color=\"green\">+0.1%</font>, <a href='https://seekingalpha.com/symbol/UBSFY' title='Ubisoft Entertainment SA'>OTCPK:UBSFY</a>, <a href='https://seekingalpha.com/symbol/NCBDY' title='Bandai Namco Holdings, Inc. ADR'>OTC:NCBDY</a>, <a href='https://seekingalpha.com/symbol/SQNNY' title='Square Enix Holdings Co., Ltd.'>OTCPK:SQNNY</a>, <a href='https://seekingalpha.com/symbol/CCOEY' title='Capcom Co., Ltd.'>OTCPK:CCOEY</a>, <a href='https://seekingalpha.com/symbol/SGAMY' title='Sega Sammy Holdings Inc.'>OTCPK:SGAMY</a>. Retail stock: <a href='https://seekingalpha.com/symbol/GME' title='GameStop Corp.'>GME</a> <font color=\"green\">+1.7%</font>.</li>    <li>ETFs: <a href='https://seekingalpha.com/symbol/GAMR' title='ETF Managers Trust - ETFMG Video Game Tech ETF'>GAMR</a>, <a href='https://seekingalpha.com/symbol/ESPO' title='VanEck Vectors ETF Trust - VanEck Vectors Video Gaming and eSports ETF'>ESPO</a>, <a href='https://seekingalpha.com/symbol/NERD' title='Listed Funds Trust - Roundhill BITKRAFT Esports & Digital Entertainment ETF'>NERD</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3519630\" data-linked=\"Strong October for videogames despite drop from record\" data-tweet=\"$NTDOY $MSFT $SNE - Strong October for videogames despite drop from record https://seekingalpha.com/news/3519630-strong-october-for-videogames-despite-drop-from-record?source=tweet\" data-url=\"https://seekingalpha.com/news/3519630-strong-october-for-videogames-despite-drop-from-record\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:51 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>19&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3519629\" data-ts=\"1573774778\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HP\" target=\"_blank\">HP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3519629-helmerich-payne-posts-q3-profit-amid-industry-pullback\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Helmerich &amp; Payne posts Q3 profit amid industry pullback</a></h4><ul><li>Helmerich &amp; Payne (NYSE:<a href='https://seekingalpha.com/symbol/HP' title='Helmerich & Payne, Inc.'>HP</a>) <font color=\"green\">+2.5%</font> after-hours after swinging to a <a href=\"https://seekingalpha.com/news/3519614-helmerich-and-payne-eps-beats-0_14-misses-revenue\" target=\"_blank\">Q3 profit</a> that also easily exceeded Wall Street expectations despite the continued pullback in industry activity.</li><li>Q3 operating income in HP's U.S. Land Operations unit swung to $59.2M from a $144.2M loss in Q2, mostly due to the impairment of drilling equipment and spares that hurt prior-quarter results; without the impairment, segment operating income declined due to sequential decreases in revenue days and adjusted average rig margin per day.</li><li>Q3 rig utilization in the U.S. Land segment rose to 68% from 62% in Q2 and 65% in the year-ago quarter.</li><li>Looking to FY 2020, HP expects customers to remain disciplined with their spending behavior and anticipates an initial capex budget of $275M-$300M, which should result in healthy free cash flow generation.</li><li>For Q1 2020 in the U.S. Land segment, HP sees revenue days falling by 5.5%-6.5% Q/Q at average rig revenue per day declining slightly to $24,750-$25,250, and it expects to exit the  quarter at 187-197 active rigs.</li></ul><div class=\"tiny-share-widget\" data-id=\"3519629\" data-linked=\"Helmerich &amp; Payne posts Q3 profit amid industry pullback\" data-tweet=\"$HP - Helmerich &amp; Payne posts Q3 profit amid industry pullback https://seekingalpha.com/news/3519629-helmerich-payne-posts-q3-profit-amid-industry-pullback?source=tweet\" data-url=\"https://seekingalpha.com/news/3519629-helmerich-payne-posts-q3-profit-amid-industry-pullback\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:39 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3519628\" data-ts=\"1573773166\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WPM\" target=\"_blank\">WPM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3519628-wheaton-precious-metals-reports-in-line-q3-raises-production-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Wheaton Precious Metals reports in-line Q3, raises production guidance</a></h4><ul><li>Wheaton Precious Metals (NYSE:<a href='https://seekingalpha.com/symbol/WPM' title='Wheaton Precious Metals Corp.'>WPM</a>) <font color=\"green\">+2%</font> after-hours as it meets expectations for <a href=\"https://seekingalpha.com/news/3519588-wheaton-precious-metals-eps-line-misses-revenue\" target=\"_blank\">Q3 earnings</a> and raises FY 2019 gold production guidance.</li><li>Q3 operating cash flow increased 31% Y/Y to $142M, resulting in  a 107% gain in adjusted net earnings to $72.7M.</li><li>WPM says Q3 attributable gold production slipped 2% Y/Y to 104.1K oz. but it remains on track for record annual gold  production in the full year; silver output rose 9% to 6.1K oz., and gold equiv. production gained less than 1% to 184.8K oz.</li><li>Q3 averaged realized gold price jumped 21% Y/Y to $1,471/oz. while the average silver price climbed 15.5% to $17.09/oz.</li><li>For the full year, WPM raises gold production guidance to 390K oz. from 385K oz. previously, due to continued outperformance primarily from the Salobo mine, while its silver production guidance is lowered to 21M oz. from 22.5M oz. to reflect production interruptions at  the Peñasquito mine.</li></ul><div class=\"tiny-share-widget\" data-id=\"3519628\" data-linked=\"Wheaton Precious Metals reports in-line Q3, raises production guidance\" data-tweet=\"$WPM - Wheaton Precious Metals reports in-line Q3, raises production guidance https://seekingalpha.com/news/3519628-wheaton-precious-metals-reports-in-line-q3-raises-production-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3519628-wheaton-precious-metals-reports-in-line-q3-raises-production-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:12 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3519626\" data-ts=\"1573773061\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ACST\" target=\"_blank\">ACST</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3519626-acasti-matinas-perk-up-on-positive-ad-com-vote-for-amarins-vascepa\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Acasti &amp; Matinas perk up on positive Ad Com vote for Amarin&#39;s Vascepa</a></h4><ul>   <li>Acasti Pharma (NASDAQ:<a href='https://seekingalpha.com/symbol/ACST' title='Acasti Pharma Inc.'>ACST</a>) and Matinas BioPharma Holdings (NYSEMKT:<a href='https://seekingalpha.com/symbol/MTNB' title='Matinas BioPharma Holdings, Inc.'>MTNB</a>) are up after hours following Amarin's <a href=\"https://seekingalpha.com/news/3519441-fda-ad-com-thumbs-cv-benefit-amarins-vascepa\" target=\"_blank\">FDA panel win</a> to expand the label for high triglyceride med Vascepa (icosapent ethyl) to include a CV benefit claim.</li>    <li>ACST is <font color=\"green\">up 12.3%</font> and and MTNB is <font color=\"green\">up 12.2%</font> in postmarket trading.</li>    <li>ACST is developing an omega-3 product, CaPre, for high triglycerides as is MTNB with MAT9001.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3519626\" data-linked=\"Acasti &amp; Matinas perk up on positive Ad Com vote for Amarin&#39;s Vascepa\" data-tweet=\"$ACST $MTNB - Acasti &amp; Matinas perk up on positive Ad Com vote for Amarin&#39;s Vascepa https://seekingalpha.com/news/3519626-acasti-matinas-perk-up-on-positive-ad-com-vote-for-amarins-vascepa?source=tweet\" data-url=\"https://seekingalpha.com/news/3519626-acasti-matinas-perk-up-on-positive-ad-com-vote-for-amarins-vascepa\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:11 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>28&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3519620\" data-ts=\"1573771827\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3519620-ftch-dgii-acb-and-dlb-among-notable-after-hour-movers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FTCH, DGII, ACB and DLB among notable after hour movers</a></h4><ul><li><strong>Gainers: </strong><a href='https://seekingalpha.com/symbol/FTCH' title='Farfetch Limited'>FTCH</a> <font color=\"green\">+21.7%</font>. <a href='https://seekingalpha.com/symbol/DGII' title='Digi International Inc.'>DGII</a> <font color=\"green\">+9.3%</font>. <a href='https://seekingalpha.com/symbol/RDNT' title='RadNet, Inc.'>RDNT</a> <font color=\"green\">+7.1%</font>. <a href='https://seekingalpha.com/symbol/RH' title='RH'>RH</a> <font color=\"green\">+6.8%</font>. <a href='https://seekingalpha.com/symbol/RBBN' title='Ribbon Communications Inc.'>RBBN</a> <font color=\"green\">+5.0%</font>.</li><li><strong>Losers: </strong><a href='https://seekingalpha.com/symbol/ACB' title='Aurora Cannabis Inc.'>ACB</a> <font color=\"red\">-8.8%</font>. <a href='https://seekingalpha.com/symbol/GLOB' title='Globant S.A.'>GLOB</a> <font color=\"red\">-5.7%</font>. <a href='https://seekingalpha.com/symbol/DLB' title='Dolby Laboratories, Inc.'>DLB</a> <font color=\"red\">-4.6%</font>. <a href='https://seekingalpha.com/symbol/MGNX' title='MacroGenics, Inc.'>MGNX</a> <font color=\"red\">-4.4%</font>. <a href='https://seekingalpha.com/symbol/XFLT' title='XAI Octagon Floating Rate & Alternative Income Term Trust'>XFLT</a> <font color=\"red\">-4.4%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3519620\" data-linked=\"FTCH, DGII, ACB and DLB among notable after hour movers\" data-tweet=\"$FTCH $DGII $RDNT - FTCH, DGII, ACB and DLB among notable after hour movers https://seekingalpha.com/news/3519620-ftch-dgii-acb-and-dlb-among-notable-after-hour-movers?source=tweet\" data-url=\"https://seekingalpha.com/news/3519620-ftch-dgii-acb-and-dlb-among-notable-after-hour-movers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:50 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3519613\" data-ts=\"1573770924\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3519613-radnetplus-9-on-addition-to-smallcap-600\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">RadNet +9% on addition to SmallCap 600</a></h4><ul>   <li>RadNet (NASDAQ:<a href='https://seekingalpha.com/symbol/RDNT' title='RadNet, Inc.'>RDNT</a>) is <font color=\"green\">up 9%</font> after hours following news it's being <a href=\"https://us.spindices.com/documents/indexnews/announcements/20191114-1034359/1034359_6radgannett.pdf?force_download=true\" target=\"_blank\">added to the S&amp;P SmallCap 600</a>.</li>    <li>It will replace Gannett (NYSE:<a href='https://seekingalpha.com/symbol/GCI' title='Gannett Co., Inc.'>GCI</a>), soon to be <a href=\"https://seekingalpha.com/news/3519320-shareholders-approve-new-media-gannett-merger\" target=\"_blank\">acquired by New Media Investment Group</a>.</li>    <li>The move is effective prior to the open of trading on Wednesday, Nov. 20.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3519613\" data-linked=\"RadNet +9% on addition to SmallCap 600\" data-tweet=\"$RDNT $GCI - RadNet +9% on addition to SmallCap 600 https://seekingalpha.com/news/3519613-radnetplus-9-on-addition-to-smallcap-600?source=tweet\" data-url=\"https://seekingalpha.com/news/3519613-radnetplus-9-on-addition-to-smallcap-600\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:35 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3519605\" data-ts=\"1573770339\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WYY\" target=\"_blank\">WYY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3519605-widepointplus-10_5-revenue-strength-leads-to-profit-improvement\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">WidePoint +10.5% as revenue strength leads to profit improvement</a></h4><ul>   <li>WidePoint (NYSEMKT:<a href='https://seekingalpha.com/symbol/WYY' title='WidePoint Corporation'>WYY</a>) is <font color=\"green\">up 10.5%</font> postmarket after essentially breaking even and surprising to the revenue upside in its <a href=\"https://seekingalpha.com/news/3519446-widepoint-beats-revenue\" target=\"_blank\">Q3 earnings</a>.</li>    <li>Revenues jumped 39% to $29.6M, and gross profit rose by 17%, to $4.3M.</li>    <li>Net income came to $184,000.</li>    <li>And EBITDA rose to $949,000, marking a ninth straight quarter in the green.</li>    <li>\"We continued building on the momentum we generated in the first half of the year by growing the topline to drive towards consistent bottom-line profitability,\u201d says CEO Jin Kang.</li>    <li>For the full year, it's reiterating guidance for revenue of $90M-$93M and EBITDA of $2.75M-$3.5M.</li>    <li><a href=\"https://seekingalpha.com/pr/17700204-widepoint-reports-third-quarter-2019-financial-results\" target=\"_blank\">Press release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3519605\" data-linked=\"WidePoint +10.5% as revenue strength leads to profit improvement\" data-tweet=\"$WYY - WidePoint +10.5% as revenue strength leads to profit improvement https://seekingalpha.com/news/3519605-widepointplus-10_5-revenue-strength-leads-to-profit-improvement?source=tweet\" data-url=\"https://seekingalpha.com/news/3519605-widepointplus-10_5-revenue-strength-leads-to-profit-improvement\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:25 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3519566\" data-ts=\"1573768751\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KMPH\" target=\"_blank\">KMPH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3519566-kempharm-eps-beats-0_34-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">KemPharm EPS beats by $0.34, beats on revenue</a></h4><ul><li>KemPharm (NASDAQ:<a href='https://seekingalpha.com/symbol/KMPH' title='KemPharm, Inc.'>KMPH</a>): Q3 GAAP EPS of $0.06 <font color=\"green\">beats by $0.34</font>.</li><li>Revenue of $11.46M <font color=\"green\">beats by $8.53M</font>.</li><li>Shares <font color=\"green\">+3.83%</font>.</li><li><a href=\"https://seekingalpha.com/pr/17700394-kempharm-reports-third-quarter-2019-results\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3519566\" data-linked=\"KemPharm EPS beats by $0.34, beats on revenue\" data-tweet=\"$KMPH - KemPharm EPS beats by $0.34, beats on revenue https://seekingalpha.com/news/3519566-kempharm-eps-beats-0_34-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3519566-kempharm-eps-beats-0_34-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:59 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3519553\" data-ts=\"1573768258\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FTCH\" target=\"_blank\">FTCH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3519553-farfetch-eps-beats-0_02-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Farfetch EPS beats by $0.02, beats on revenue</a></h4><ul><li>Farfetch (NYSE:<a href='https://seekingalpha.com/symbol/FTCH' title='Farfetch Limited'>FTCH</a>): Q3 Non-GAAP EPS of -$0.18 <font color=\"green\">beats by $0.02</font>; GAAP EPS of -$0.28 <font color=\"green\">beats by $0.04</font>.</li><li>Revenue of $255.48M (+89.9% Y/Y) <font color=\"green\">beats by $7.17M</font>.</li><li>Shares <font color=\"green\">+19.8%</font>.</li><li><a href=\"https://seekingalpha.com/filing/4700339\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3519553\" data-linked=\"Farfetch EPS beats by $0.02, beats on revenue\" data-tweet=\"$FTCH - Farfetch EPS beats by $0.02, beats on revenue https://seekingalpha.com/news/3519553-farfetch-eps-beats-0_02-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3519553-farfetch-eps-beats-0_02-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:50 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3519524\" data-ts=\"1573767614\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AGRX\" target=\"_blank\">AGRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3519524-fda-extends-action-date-on-agiles-twirla-shares-down-39-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA extends action date on Agile&#39;s Twirla; shares down 39% after hours</a></h4><ul><li>Agile Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/AGRX' title='Agile Therapeutics, Inc.'>AGRX</a>) slumps <font color=\"red\">39%</font> after-hours on the news that the FDA has extended its action date for its decision on the company's marketing application for contraceptive patch Twirla (levonorgestrel/ethinyl estradiol) transdermal system.</li><li>The new PDUFA date is February 16, 2020 (from this Saturday, November 16).</li><li>On October 30, an FDA advisory panel <a href=\"https://seekingalpha.com/news/3511749-fda-advisory-committee-back-agiles-twirla\" target=\"_blank\">voted 14-1</a> in favor of approval. It's been a long slog for the company considering it has been pursuing the FDA nod since 2012.</li></ul><div class=\"tiny-share-widget\" data-id=\"3519524\" data-linked=\"FDA extends action date on Agile&#39;s Twirla; shares down 39% after hours\" data-tweet=\"$AGRX - FDA extends action date on Agile&#39;s Twirla; shares down 39% after hours https://seekingalpha.com/news/3519524-fda-extends-action-date-on-agiles-twirla-shares-down-39-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3519524-fda-extends-action-date-on-agiles-twirla-shares-down-39-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:40 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3519513\" data-ts=\"1573767365\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3519513-nvidiaplus-1-after-beats-gaming-strength\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nvidia +1% after beats, gaming strength</a></h4><ul><li>Nvidia (NASDAQ:<a href='https://seekingalpha.com/symbol/NVDA' title='NVIDIA Corporation'>NVDA</a>) <font color=\"green\">+1.2%</font> reports <a href=\"https://seekingalpha.com/news/3519480-nvidia-eps-beats-0_20-beats-revenue\" target=\"_blank\">Q3 beats</a> with downside Q4 guidance that sees revenue of $2.89-3.01B (consensus: $3.08B) with a 64.5% gross margin.</li><li>NVDA expects strong sequential growth in Data Center, offset by seasonal declines in GeForce notebook GPUs and SoC modules for gaming.</li><li>Q3 revenue by market platform: Gaming, $1.66B (+26% Q/Q; -6% Y/Y); Professional Visualization, $324M (+11% Q/Q; +6% Y/Y); Data Center, $726M (+11% Q/Q; -8% Y/Y); Auto, $162M (-22% Q/Q; -6% Y/Y); OEM and Other, $143M (+29% Q/Q; -3% Y/Y).</li><li>Earnings call starts at 5:30 PM with a webcast <a href=\"https://investor.nvidia.com/home/default.aspx\" target=\"_blank\">here</a>.</li><li><a href=\"https://seekingalpha.com/pr/17700307-nvidia-announces-financial-results-third-quarter-fiscal-2020\" target=\"_blank\">Press release</a> /<a href=\"https://investor.nvidia.com/home/default.aspx\" target=\"_blank\"> CFO commentary</a></li><li>Gross margin was 64.1% compared to the 61% in last year's quarter and 62.5% consensus.</li></ul><div class=\"tiny-share-widget\" data-id=\"3519513\" data-linked=\"Nvidia +1% after beats, gaming strength\" data-tweet=\"$NVDA - Nvidia +1% after beats, gaming strength https://seekingalpha.com/news/3519513-nvidiaplus-1-after-beats-gaming-strength?source=tweet\" data-url=\"https://seekingalpha.com/news/3519513-nvidiaplus-1-after-beats-gaming-strength\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:36 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>73&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3519505\" data-ts=\"1573767113\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SORL\" target=\"_blank\">SORL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3519505-sorl-auto-eps-beats-0_04-misses-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">SORL Auto EPS beats by $0.04, misses on revenue</a></h4><ul><li>SORL Auto (NASDAQ:<a href='https://seekingalpha.com/symbol/SORL' title='SORL Auto Parts, Inc.'>SORL</a>): Q3 GAAP EPS of $0.22 <font color=\"green\">beats by $0.04</font>.</li><li>Revenue of $112.2M (+3.3% Y/Y) <font color=\"red\">misses by $3.6M</font>.</li><li>Shares <font color=\"green\">+1.8%</font>.</li><li><a href=\"https://seekingalpha.com/pr/17700314-sorl-auto-parts-announces-third-quarter-record-high-sales-2019\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3519505\" data-linked=\"SORL Auto EPS beats by $0.04, misses on revenue\" data-tweet=\"$SORL - SORL Auto EPS beats by $0.04, misses on revenue https://seekingalpha.com/news/3519505-sorl-auto-eps-beats-0_04-misses-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3519505-sorl-auto-eps-beats-0_04-misses-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:31 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3519497\" data-ts=\"1573766939\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DGII\" target=\"_blank\">DGII</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3519497-digi-internationalplus-9_1-after-q4-tops-street-view\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Digi International +9.1% after Q4 tops Street view</a></h4><ul>   <li>Digi International (NASDAQ:<a href='https://seekingalpha.com/symbol/DGII' title='Digi International Inc.'>DGII</a>) is <font color=\"green\">up 9.1%</font> postmarket after clearing expectations for its <a href=\"https://seekingalpha.com/news/3519435-digi-international-eps-beats-0_13-beats-revenue\" target=\"_blank\">fiscal Q4 report</a>.</li>    <li>Revenue dipped fractionally to $64.96M, though adjusted EBITDA rose 3.3% to $7.6M.</li>    <li>Net income fell to $2.3M from $3.3M.</li>    <li>Revenue by segment: IoT Product &amp; Services, $55.5M (down 1.7%) amid lower sales of celllular and network offerings; IoT Solutions, $9.5M (up 9.1%), boosted by a rise in recurring subscriptions.</li>    <li>For Q1 2020, it's guiding to revenue of $58M-$62M (below consensus for $64.4M), EBITDA of $5M-$6M, and EPS of $0.10-$0.14 (above an expected $0.07)</li>    <li>For the full year, it's forecasting revenues of $310M-$325M (incorporating about nine months of results from a pending acquisition of Opengear), above expectations for $272.3M; EBITDA of $45M-$50M; and EPS of $1.14-$1.27 (above expectations for $0.52).</li>    <li><a href=\"https://edge.media-server.com/mmc/p/dhnwpor4\" target=\"_blank\">Conference call</a> to come at 5 p.m. ET.</li>    <li><a href=\"https://seekingalpha.com/pr/17700199-digi-international-reports-fiscal-fourth-quarter-full-fiscal-year-2019-results\" target=\"_blank\">Press release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3519497\" data-linked=\"Digi International +9.1% after Q4 tops Street view\" data-tweet=\"$DGII - Digi International +9.1% after Q4 tops Street view https://seekingalpha.com/news/3519497-digi-internationalplus-9_1-after-q4-tops-street-view?source=tweet\" data-url=\"https://seekingalpha.com/news/3519497-digi-internationalplus-9_1-after-q4-tops-street-view\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:28 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3519490\" data-ts=\"1573766758\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TCDA\" target=\"_blank\">TCDA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3519490-tricida-eps-beats-0_03\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tricida EPS beats by $0.03</a></h4><ul><li>Tricida (NASDAQ:<a href='https://seekingalpha.com/symbol/TCDA' title='Tricida, Inc.'>TCDA</a>): Q3 GAAP EPS of -$0.89 <font color=\"green\">beats by $0.03</font>.</li><li>Cash, equivalents and investments of $363.6M</li><li>Shares <font color=\"green\">+2.51%</font>.</li><li><a href=\"https://seekingalpha.com/pr/17700240-tricida-announces-third-quarter-2019-financial-results\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3519490\" data-linked=\"Tricida EPS beats by $0.03\" data-tweet=\"$TCDA - Tricida EPS beats by $0.03 https://seekingalpha.com/news/3519490-tricida-eps-beats-0_03?source=tweet\" data-url=\"https://seekingalpha.com/news/3519490-tricida-eps-beats-0_03\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:25 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3519488\" data-ts=\"1573766704\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3519488-berkshire-hathaway-takes-stake-in-rh\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Berkshire Hathaway takes stake in RH</a></h4><ul><li>RH (NYSE:<a href='https://seekingalpha.com/symbol/RH' title='RH'>RH</a>) is <font color=\"green\">up 6.65%</font> in AH trading after Berkshire Hathaway (<a href='https://seekingalpha.com/symbol/BRK.A' title='Berkshire Hathaway Inc.'>BRK.A</a>, <a href='https://seekingalpha.com/symbol/BRK.B' title='Berkshire Hathaway Inc.'>BRK.B</a>) <a href=\"https://www.sec.gov/Archives/edgar/data/1067983/000095012319011362/xslForm13F_X01/primary_doc.xml\" target=\"_blank\">discloses</a> holding a stake in the retailer.</li><li>Berkshire took a position in RH of ~1.21M shares.</li><li>Shares of RH are up 46% YTD.</li></ul><div class=\"tiny-share-widget\" data-id=\"3519488\" data-linked=\"Berkshire Hathaway takes stake in RH\" data-tweet=\"$RH $BRK.A $BRK.B - Berkshire Hathaway takes stake in RH https://seekingalpha.com/news/3519488-berkshire-hathaway-takes-stake-in-rh?source=tweet\" data-url=\"https://seekingalpha.com/news/3519488-berkshire-hathaway-takes-stake-in-rh\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:25 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>54&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3519452\" data-ts=\"1573765958\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMAT\" target=\"_blank\">AMAT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3519452-amatplus-3_8-after-q4-beats-upside-outlook\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AMAT +3.8% after Q4 beats, upside outlook</a></h4><ul><li>Applied Materials (NASDAQ:<a href='https://seekingalpha.com/symbol/AMAT' title='Applied Materials, Inc.'>AMAT</a>) <font color=\"green\">+3.8%</font> <a href=\"https://seekingalpha.com/news/3519424-applied-materials-eps-beats-0_04-beats-revenue\" target=\"_blank\">beats Q4</a> estimates and guides an upside Q1 with revenue of $4.1B plus or minus $150M (consensus: $3.71B) and EPS of $0.87-0.95 (consensus: $0.74)</li><li>Q4 revenue breakdown: Semi Systems, $2.3B (consensus: $2.25B); Applied Global Services, $977M (consensus: $956M); Display and Adjacent Markets, $457M (consensus: $455.2M);</li><li>Gross margin was 43.8% compared to the 45.5% in last year's quarter and the 43.4% consensus.</li><li>Earnings call starts at 4:30 PM with a webcast <a href=\"https://www.globenewswire.com/Tracker?data=eoRdUeIw0y2fqfdXgV5rUCmKxHSkevjV3yh3ouklxCYPRcAW4dEXKv2m_F68YcZGF9_OjD3_6GtPCyarQ2qzWWbxoDXtvevW6ODcUzYVIsw=\" target=\"_blank\">here</a>.</li><li><a href=\"https://seekingalpha.com/pr/17700183-applied-materials-announces-fourth-quarter-fiscal-year-2019-results\" target=\"_blank\">Press release</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3519452\" data-linked=\"AMAT +3.8% after Q4 beats, upside outlook\" data-tweet=\"$AMAT - AMAT +3.8% after Q4 beats, upside outlook https://seekingalpha.com/news/3519452-amatplus-3_8-after-q4-beats-upside-outlook?source=tweet\" data-url=\"https://seekingalpha.com/news/3519452-amatplus-3_8-after-q4-beats-upside-outlook\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:12 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3519447\" data-ts=\"1573765824\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TTNP\" target=\"_blank\">TTNP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3519447-titan-pharmaceuticals-eps-beats-0_03-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Titan Pharmaceuticals EPS beats by $0.03, beats on revenue</a></h4><ul><li>Titan Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/TTNP' title='Titan Pharmaceuticals, Inc.'>TTNP</a>): Q3 GAAP EPS of -$0.18 <font color=\"green\">beats by $0.03</font>.</li><li>Revenue of $0.95M (-42.4% Y/Y) <font color=\"green\">beats by $0.25M</font>.</li><li>Shares <font color=\"green\">+5.89%</font>.</li><li><a href=\"https://seekingalpha.com/pr/17700191-titan-pharmaceuticals-reports-third-quarter-2019-financial-results\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3519447\" data-linked=\"Titan Pharmaceuticals EPS beats by $0.03, beats on revenue\" data-tweet=\"$TTNP - Titan Pharmaceuticals EPS beats by $0.03, beats on revenue https://seekingalpha.com/news/3519447-titan-pharmaceuticals-eps-beats-0_03-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3519447-titan-pharmaceuticals-eps-beats-0_03-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:10 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3519446\" data-ts=\"1573765813\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WYY\" target=\"_blank\">WYY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3519446-widepoint-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">WidePoint beats on revenue</a></h4><ul><li>WidePoint (NYSEMKT:<a href='https://seekingalpha.com/symbol/WYY' title='WidePoint Corporation'>WYY</a>): Q3 GAAP EPS of $0.00.</li><li>Revenue of $29.6M (+39.0% Y/Y) <font color=\"green\">beats by $6.64M</font>.</li><li>Shares <font color=\"green\">+1.91%</font>.</li><li><a href=\"https://seekingalpha.com/pr/17700204-widepoint-reports-third-quarter-2019-financial-results\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3519446\" data-linked=\"WidePoint beats on revenue\" data-tweet=\"$WYY - WidePoint beats on revenue https://seekingalpha.com/news/3519446-widepoint-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3519446-widepoint-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:10 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3519441\" data-ts=\"1573765750\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMRN\" target=\"_blank\">AMRN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3519441-fda-ad-com-thumbs-up-on-cv-benefit-of-amarins-vascepa\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA Ad Com thumbs up on CV benefit of Amarin&#39;s Vascepa</a></h4><ul><li>The FDA's Endocrinologic and Metabolic Drugs Advisory Committee voted 16-0 backing the cardiovascular &#40;CV&#41; benefit of Amarin's (NASDAQ:<a href='https://seekingalpha.com/symbol/AMRN' title='Amarin Corporation plc'>AMRN</a>) Vascepa (icosapent ethyl).</li><li>The key remaining question is the specific breadth of the label (the approved population).</li></ul><div class=\"tiny-share-widget\" data-id=\"3519441\" data-linked=\"FDA Ad Com thumbs up on CV benefit of Amarin&#39;s Vascepa\" data-tweet=\"$AMRN - FDA Ad Com thumbs up on CV benefit of Amarin&#39;s Vascepa https://seekingalpha.com/news/3519441-fda-ad-com-thumbs-up-on-cv-benefit-of-amarins-vascepa?source=tweet\" data-url=\"https://seekingalpha.com/news/3519441-fda-ad-com-thumbs-up-on-cv-benefit-of-amarins-vascepa\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:09 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>174&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3519439\" data-ts=\"1573765696\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EYES\" target=\"_blank\">EYES</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3519439-second-sight-eps-in-line-misses-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Second Sight EPS in-line, misses on revenue</a></h4><ul><li>Second Sight (NASDAQ:<a href='https://seekingalpha.com/symbol/EYES' title='Second Sight Medical Products, Inc.'>EYES</a>): Q3 GAAP EPS of -$0.06 in-line.</li><li>Revenue of $0.47M (-79.1% Y/Y) <font color=\"red\">misses by $0.47M</font>.</li><li>Shares <font color=\"green\">+5.9%</font>.</li><li><a href=\"https://seekingalpha.com/pr/17700193-second-sight-reports-third-quarter-2019-financial-results\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3519439\" data-linked=\"Second Sight EPS in-line, misses on revenue\" data-tweet=\"$EYES - Second Sight EPS in-line, misses on revenue https://seekingalpha.com/news/3519439-second-sight-eps-in-line-misses-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3519439-second-sight-eps-in-line-misses-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:08 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3519424\" data-ts=\"1573765377\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMAT\" target=\"_blank\">AMAT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3519424-applied-materials-eps-beats-0_04-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Applied Materials EPS beats by $0.04, beats on revenue</a></h4><ul><li>Applied Materials (NASDAQ:<a href='https://seekingalpha.com/symbol/AMAT' title='Applied Materials, Inc.'>AMAT</a>): Q4 Non-GAAP EPS of $0.80 <font color=\"green\">beats by $0.04</font>; GAAP EPS of $0.75 in-line.</li><li>Revenue of $3.75B (-0.3% Y/Y) <font color=\"green\">beats by $70M</font>.</li><li>Shares <font color=\"green\">+4%</font>.</li><li><a href=\"https://seekingalpha.com/pr/17700183-applied-materials-announces-fourth-quarter-fiscal-year-2019-results\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3519424\" data-linked=\"Applied Materials EPS beats by $0.04, beats on revenue\" data-tweet=\"$AMAT - Applied Materials EPS beats by $0.04, beats on revenue https://seekingalpha.com/news/3519424-applied-materials-eps-beats-0_04-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3519424-applied-materials-eps-beats-0_04-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:02 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3519412\" data-ts=\"1573764468\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BGNE\" target=\"_blank\">BGNE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3519412-fda-oks-beigenes-zanubrutinib-for-mantle-cell-lymphoma\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA OKs BeiGene&#39;s zanubrutinib for mantle cell lymphoma</a></h4><ul><li>The FDA grants <a href=\"https://www.fda.gov/news-events/press-announcements/fda-approves-therapy-treat-patients-relapsed-and-refractory-mantle-cell-lymphoma-supported-clinical\" target=\"_blank\">accelerated approval</a> to BeiGene's (<a href='https://seekingalpha.com/symbol/BGNE' title='BeiGene, Ltd.'>BGNE</a> <font color=\"red\">-0.6%</font>) BTK inhibitor zanubrutinib, branded as Brukinsa, for the treatment of mantle cell lymphoma, an aggressive type of non-Hodgkin lymphoma, its first approved drug in the U.S. The approved use is for patients who have received at least one prior line of therapy.</li><li>Zanubrutinib had Breakthrough Therapy and Orphan Drug status for the indication.</li><li><strong>Update</strong>: Shares up <font color=\"green\">6%</font> after hours.</li></ul><div class=\"tiny-share-widget\" data-id=\"3519412\" data-linked=\"FDA OKs BeiGene&#39;s zanubrutinib for mantle cell lymphoma\" data-tweet=\"$BGNE - FDA OKs BeiGene&#39;s zanubrutinib for mantle cell lymphoma https://seekingalpha.com/news/3519412-fda-oks-beigenes-zanubrutinib-for-mantle-cell-lymphoma?source=tweet\" data-url=\"https://seekingalpha.com/news/3519412-fda-oks-beigenes-zanubrutinib-for-mantle-cell-lymphoma\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:47 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3519409\" data-ts=\"1573763960\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3519409-ny-airport-regulator-partners-uber-rival\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">NY airport regulator partners with Uber rival</a></h4><ul><li>Ride-share provider Via <a href=\"https://www.nytimes.com/reuters/2019/11/14/technology/14reuters-via-new-york.html\" target=\"_blank\">partners</a> with the Port Authority of New York and New Jersey for flat-rate shared trips from LaGuardia Airport.</li><li>The service will cost $15 to all NYC boroughs or $20 to destinations like Bronx and Staten Island.</li><li>Four to six passengers will share a ride, which aims to help with LaGuardia's notorious congestion. Via will use its algorithm to group passengers in the most efficient way.</li><li>The flat-rate cost is at least half the price of rides from Uber (<a href='https://seekingalpha.com/symbol/UBER' title='Uber Technologies, Inc.'>UBER</a> <font color='red'>-2.7%</font>) and Lyft (<a href='https://seekingalpha.com/symbol/LYFT' title='Lyft, Inc.'>LYFT</a> <font color='red'>-3.2%</font>).</li></ul><div class=\"tiny-share-widget\" data-id=\"3519409\" data-linked=\"NY airport regulator partners with Uber rival\" data-tweet=\"$UBER $LYFT - NY airport regulator partners with Uber rival https://seekingalpha.com/news/3519409-ny-airport-regulator-partners-uber-rival?source=tweet\" data-url=\"https://seekingalpha.com/news/3519409-ny-airport-regulator-partners-uber-rival\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:39 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3519407\" data-ts=\"1573763478\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LPTX\" target=\"_blank\">LPTX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3519407-leap-therapeutics-bails-on-2-program-shares-down-43\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Leap Therapeutics bails on #2 program; shares down 43%</a></h4><ul><li>Nano cap Leap Therapeutics (<a href='https://seekingalpha.com/symbol/LPTX' title='Leap Therapeutics, Inc.'>LPTX</a> <font color=\"red\">-42.6%</font>) plummets on a 10x surge in volume in apparent response to its <a href=\"https://seekingalpha.com/pr/17698959-leap-therapeutics-reports-third-quarter-2019-financial-results\" target=\"_blank\">disclosure </a>that it will \"de-prioritize\" further development of TRX518, its #2 candidate in Phase 2 development for solid tumors.</li><li>The company says the move will enable it to sharpen its focus on lead drug DKN-01, in Phase 2 development for gynecological cancers.</li><li>At the end of September, it had $10.1M in quick assets while operations consumed ($21.0M) during the first nine months of the year.</li></ul><div class=\"tiny-share-widget\" data-id=\"3519407\" data-linked=\"Leap Therapeutics bails on #2 program; shares down 43%\" data-tweet=\"$LPTX - Leap Therapeutics bails on #2 program; shares down 43% https://seekingalpha.com/news/3519407-leap-therapeutics-bails-on-2-program-shares-down-43?source=tweet\" data-url=\"https://seekingalpha.com/news/3519407-leap-therapeutics-bails-on-2-program-shares-down-43\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:31 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3519402\" data-ts=\"1573761592\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3519402-sina-xnet-rbbn-and-opra-among-tech-movers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">SINA, XNET, RBBN and OPRA among tech movers</a></h4><ul><li><strong>Gainers: </strong>Alithya Group (NASDAQ:<a href='https://seekingalpha.com/symbol/ALYA' title='Alithya Group Inc.'>ALYA</a>) <font color=\"green\">+23%</font>.</li><li>Opera Limited (NASDAQ:<a href='https://seekingalpha.com/symbol/OPRA' title='Opera Limited'>OPRA</a>) <font color=\"green\">+14%</font>.</li><li>Ping Identity Holding (NYSE:<a href='https://seekingalpha.com/symbol/PING' title='Ping Identity Holding Corp.'>PING</a>) <font color=\"green\">+14%</font>.</li><li>Cango (NYSE:<a href='https://seekingalpha.com/symbol/CANG' title='Cango Inc.'>CANG</a>) <font color=\"green\">+13%</font>.</li><li>Phoenix New Media (NYSE:<a href='https://seekingalpha.com/symbol/FENG' title='Phoenix New Media Limited'>FENG</a>) <font color=\"green\">+11%</font>.</li> <li><strong>Losers: </strong>Ideanomics (NASDAQ:<a href='https://seekingalpha.com/symbol/IDEX' title='Ideanomics, Inc.'>IDEX</a>) <font color=\"red\">-31%</font>.</li><li>Westell Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/WSTL' title='Westell Technologies, Inc.'>WSTL</a>) <font color=\"red\">-29%</font>.</li><li>Ribbon Communications (NASDAQ:<a href='https://seekingalpha.com/symbol/RBBN' title='Ribbon Communications Inc.'>RBBN</a>) <font color=\"red\">-24%</font>.</li><li>Xunlei Limited (NASDAQ:<a href='https://seekingalpha.com/symbol/XNET' title='Xunlei Limited'>XNET</a>) <font color=\"red\">-18%</font>.</li><li>SINA Corporation (NASDAQ:<a href='https://seekingalpha.com/symbol/SINA' title='SINA Corporation'>SINA</a>) <font color=\"red\">-17%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3519402\" data-linked=\"SINA, XNET, RBBN and OPRA among tech movers\" data-tweet=\"$ALYA $OPRA $PING - SINA, XNET, RBBN and OPRA among tech movers https://seekingalpha.com/news/3519402-sina-xnet-rbbn-and-opra-among-tech-movers?source=tweet\" data-url=\"https://seekingalpha.com/news/3519402-sina-xnet-rbbn-and-opra-among-tech-movers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:59 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3519632\" data-ts=\"1573761499\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BA\" target=\"_blank\">BA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3519632-boeing-bumps-higher-vertical-analyst-lifts-price-target\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Boeing bumps higher as Vertical analyst lifts price target</a></h4><ul><li>Boeing (<a href='https://seekingalpha.com/symbol/BA' title='The Boeing Company'>BA</a> <font color='green'>+1.4%</font>) is today's biggest gainer on the Dow Jones Index, as shares continue to show resilience in the face of mostly negative news.</li><li>The stock may have been helped by <a href=\"https://www.marketwatch.com/story/boeings-stock-rallies-to-pace-dow-gainers-verticals-stallard-bumps-up-price-target-2019-11-14\" target=\"_blank\">bullish comments</a> from Vertical Research Partners analyst Robert Stallard, who reiterated his Buy rating and raised his price target to $400 from $380.</li><li>Boeing is \"a tough stock to call,\" given the upside potential once the 737 MAX overhang is lifted, coupled with a more challenging longer-term outlook, Stallard says.</li><li>The MAX's return to flight and clarification on the associated charges likely would remove an overhang for the stock, but Boeing will not be in a position to just \"turn back the clock\" to what life was like before the MAX grounding, Stallard says, as investors may be be \"much more circumspect\" in their projections for future cash generation and the appropriate valuation multiples.</li></ul><div class=\"tiny-share-widget\" data-id=\"3519632\" data-linked=\"Boeing bumps higher as Vertical analyst lifts price target\" data-tweet=\"$BA - Boeing bumps higher as Vertical analyst lifts price target https://seekingalpha.com/news/3519632-boeing-bumps-higher-vertical-analyst-lifts-price-target?source=tweet\" data-url=\"https://seekingalpha.com/news/3519632-boeing-bumps-higher-vertical-analyst-lifts-price-target\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:58 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>40&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3519398\" data-ts=\"1573760089\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CCMP\" target=\"_blank\">CCMP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3519398-ccmpminus-2-loop-capital-turns-cautious\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CCMP -2% as Loop Capital turns cautious</a></h4><ul><li>Loop Capital cuts Cabot Microelectronics (NASDAQ:<a href='https://seekingalpha.com/symbol/CCMP' title='Cabot Microelectronics Corporation'>CCMP</a>) from Buy to Hold with a $156 price target, a 1% downside. The company has a Bullish average <a href=\"https://seekingalpha.com/symbol/CCMP/ratings/sell-side-ratings\" target=\"_blank\">Sell Side rating</a>.</li><li>The firm cites valuation. CCMP shares are <font color=\"green\">up 9%</font> in the past month and nearly <font color=\"green\">33%</font> in the quarter.</li><li>Upcoming catalyst: CCMP reports earnings on November 17.</li><li>Cabot shares are d<font color=\"red\">own 2.3%</font> to $153.24.</li></ul><div class=\"tiny-share-widget\" data-id=\"3519398\" data-linked=\"CCMP -2% as Loop Capital turns cautious\" data-tweet=\"$CCMP - CCMP -2% as Loop Capital turns cautious https://seekingalpha.com/news/3519398-ccmpminus-2-loop-capital-turns-cautious?source=tweet\" data-url=\"https://seekingalpha.com/news/3519398-ccmpminus-2-loop-capital-turns-cautious\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:34 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3519393\" data-ts=\"1573758045\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3519393-intrepid-potash-and-golden-star-resources-among-energy-materials-gainers-pacific-coast-oil\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Intrepid Potash and Golden Star Resources among Energy/Materials gainers; Pacific Coast Oil Trust and SandRidge Permian Trust among losers</a></h4><ul><li><b>Gainers: </b>Intrepid Potash (NYSE:<a href='https://seekingalpha.com/symbol/IPI' title='Intrepid Potash, Inc.'>IPI</a>) <font color=\"green\">+10%</font>. Golden Star Resources Ltd. (NYSEMKT:<a href='https://seekingalpha.com/symbol/GSS' title='Golden Star Resources Ltd.'>GSS</a>) <font color=\"green\">+5%</font>. Auryn Resources Inc. (NYSEMKT:<a href='https://seekingalpha.com/symbol/AUG' title='Auryn Resources Inc.'>AUG</a>) <font color=\"green\">+5%</font>.</li><li><b>Losers: </b>Pacific Coast Oil Trust (NYSE:<a href='https://seekingalpha.com/symbol/ROYT' title='Pacific Coast Oil Trust'>ROYT</a>) <font color=\"red\">-74%</font>. SandRidge Permian Trust (NYSE:<a href='https://seekingalpha.com/symbol/PER' title='SandRidge Permian Trust'>PER</a>) <font color=\"red\">-9%</font>. KLX Energy Services (NASDAQ:<a href='https://seekingalpha.com/symbol/KLXE' title='KLX Energy Services Holdings, Inc.'>KLXE</a>) <font color=\"red\">-7%</font>. Antero Resources (NYSE:<a href='https://seekingalpha.com/symbol/AR' title='Antero Resources Corporation'>AR</a>) <font color=\"red\">-7%</font>. Noble Corporation (NYSE:<a href='https://seekingalpha.com/symbol/NE' title='Noble Corporation plc'>NE</a>) <font color=\"red\">-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3519393\" data-linked=\"Intrepid Potash and Golden Star Resources among Energy/Materials gainers; Pacific Coast Oil Trust and SandRidge Permian Trust among losers\" data-tweet=\"$IPI $GSS $AUG - Intrepid Potash and Golden Star Resources among Energy/Materials gainers; Pacific Coast Oil Trust and SandRidge Permian Trust among losers https://seekingalpha.com/news/3519393-intrepid-potash-and-golden-star-resources-among-energy-materials-gainers-pacific-coast-oil?source=tweet\" data-url=\"https://seekingalpha.com/news/3519393-intrepid-potash-and-golden-star-resources-among-energy-materials-gainers-pacific-coast-oil\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3519404\" data-ts=\"1573757338\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PUMP\" target=\"_blank\">PUMP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3519404-propetro-says-no-customer-impact-from-probes\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ProPetro says no customer impact from probes</a></h4><ul><li>ProPetro (<a href='https://seekingalpha.com/symbol/PUMP' title='ProPetro Holding Corp.'>PUMP</a> <font color=\"green\">+4.6%</font>) bounces off 52-week lows after reporting <a href=\"https://seekingalpha.com/news/3519044-prppetro-identifies-accounting-weaknesses-q3-results-beat-estimates\" target=\"_blank\">better than expected Q3 results</a> and saying it has <a href=\"https://www.reuters.com/article/propetro-results/propetro-says-no-customer-impact-from-sec-disclosures-probes-idUSL2N27U0L5\" target=\"_blank\">not lost customers</a> in the wake of a board probe into the company's financial disclosures and an SEC investigation.</li><li>Despite uncovering material weaknesses in its financial controls, the company says it does not expect to restate prior results.</li><li>But Goldman Sachs does not like the long-term view, <a href=\"https://thefly.com/thestreet/realmoney/index.php/PUMPid2994018/PUMP-ProPetro-Holding-downgraded-to-Neutral-from-Buy-at-Goldman-Sachs\" target=\"_blank\">downgrading</a> PUMP to  Neutral from Buy with a $10 price target, cut from $15.</li><li>The firm thinks the uncertainties surrounding the company's delayed filings, the  recently initiated SEC probe and the newly disclosed conflicts of interest in a real estate transaction will remain an overhang on the stock's valuation.</li></ul><div class=\"tiny-share-widget\" data-id=\"3519404\" data-linked=\"ProPetro says no customer impact from probes\" data-tweet=\"$PUMP - ProPetro says no customer impact from probes https://seekingalpha.com/news/3519404-propetro-says-no-customer-impact-from-probes?source=tweet\" data-url=\"https://seekingalpha.com/news/3519404-propetro-says-no-customer-impact-from-probes\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:48 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3519383\" data-ts=\"1573756637\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MRVL\" target=\"_blank\">MRVL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3519383-marvell-sinks-ciscos-forecast-disappoints\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Marvell sinks as Cisco&#39;s forecast disappoints</a></h4><ul><li>Marvell (<a href='https://seekingalpha.com/symbol/MRVL' title='Marvell Technology Group Ltd.'>MRVL</a> <font color='red'>-4.2%</font>) drops after key customer Cisco reported earnings with a <a href=\"https://seekingalpha.com/news/3518915-cisco-minus-4_7-percent-q2-forecast-disappoints\" target=\"_blank\">disappointing outlook</a>. Cisco accounts for about 11% of Marvell's revenue, according to Bloomberg data.</li><li>Raymond James (Market Perform) thinks Cisco was the reason for MRVL's networking revenue decline. The outlook suggests another step down that isn't priced into the firm's current estimates and likely isn't priced into consensus.</li><li>Wells Fargo (Outperform) is \"wondering about the degree to which MRVL\u2019s sales to Cisco can improve,\" but the firm still sees Marvell on the path to recovery largely due to 5G.</li></ul><div class=\"tiny-share-widget\" data-id=\"3519383\" data-linked=\"Marvell sinks as Cisco&#39;s forecast disappoints\" data-tweet=\"$MRVL - Marvell sinks as Cisco&#39;s forecast disappoints https://seekingalpha.com/news/3519383-marvell-sinks-ciscos-forecast-disappoints?source=tweet\" data-url=\"https://seekingalpha.com/news/3519383-marvell-sinks-ciscos-forecast-disappoints\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:37 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3519382\" data-ts=\"1573756633\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PRTY\" target=\"_blank\">PRTY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3519382-party-city-bounces-off-52-week-low\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Party City bounces off 52-week low</a></h4><ul> <li>Party City (<a href='https://seekingalpha.com/symbol/PRTY' title='Party City Holdco Inc.'>PRTY</a> <font color='green'>+12.8%</font>) has retraced most of yesterday's loss tied to a distribution of shares by Thomas H. Lee.</li> <li>Party City slipped to a 52-week low of $1.61 during Wednesday's session.</li> <li>Previously: <a href=\"https://seekingalpha.com/news/3518677-party-city-minus-14-percent-key-holder-distributes-shares\" target=\"_blank\">Party City -14% after key holder distributes shares</a> (Nov. 13)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3519382\" data-linked=\"Party City bounces off 52-week low\" data-tweet=\"$PRTY - Party City bounces off 52-week low https://seekingalpha.com/news/3519382-party-city-bounces-off-52-week-low?source=tweet\" data-url=\"https://seekingalpha.com/news/3519382-party-city-bounces-off-52-week-low\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:37 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3519381\" data-ts=\"1573756115\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALKS\" target=\"_blank\">ALKS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3519381-biogen-off-3-ms-society-takes-issue-vumerity-cost\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Biogen off 3% as MS Society takes issue with Vumerity cost</a></h4><ul><li>In a <a href=\"https://www.nationalmssociety.org/About-the-Society/News/National-MS-Society-Responds-to-Price-of-New-Bioge\" target=\"_blank\">statement </a>released yesterday, the National MS Society expressed disappointment with the wholesale acquisition cost &#40;WAC&#41; of Vumerity (diroximel fumarate), approved by FDA on October 30 for relapsing forms of multiple sclerosis &#40;MS&#41;.</li><li>The Society considers the $88K WAC excessive, citing that the price is only $500 lower than the least expensive oral disease-modifying treatment and \"does not show the commitment to affordable access that we had hoped.\"</li><li>The compound was initially developed by Alkermes (<a href='https://seekingalpha.com/symbol/ALKS' title='Alkermes plc'>ALKS</a> <font color=\"green\">+1.3%</font>) and exclusively licensed to Biogen (<a href='https://seekingalpha.com/symbol/BIIB' title='Biogen Inc.'>BIIB</a> <font color=\"red\">-2.7%</font>) in November 2017.</li><li>Biogen, like almost all other biotechs, has a track record of consistent price hikes for its medicines. For example, Tecfidera (dimethyl fumarate), was approved in the U.S. for relapsing forms of MS in March 2013 at a WAC of $54,750 which has increased over $40K to today's WAC of $94,991, a compounded increase of almost 10% annually.</li></ul><div class=\"tiny-share-widget\" data-id=\"3519381\" data-linked=\"Biogen off 3% as MS Society takes issue with Vumerity cost\" data-tweet=\"$ALKS $BIIB - Biogen off 3% as MS Society takes issue with Vumerity cost https://seekingalpha.com/news/3519381-biogen-off-3-ms-society-takes-issue-vumerity-cost?source=tweet\" data-url=\"https://seekingalpha.com/news/3519381-biogen-off-3-ms-society-takes-issue-vumerity-cost\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:28 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3519378\" data-ts=\"1573755366\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3519378-mgi-leads-financial-gainers-mtc-and-bma-among-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MGI leads financial gainers; MTC and BMA among losers</a></h4><ul><li><b>Gainers:</b> MoneyGram International (NASDAQ:<a href='https://seekingalpha.com/symbol/MGI' title='MoneyGram International, Inc.'>MGI</a>) <font color=\"green\">+8%</font>. Realogy Holdings (NYSE:<a href='https://seekingalpha.com/symbol/RLGY' title='Realogy Holdings Corp.'>RLGY</a>) <font color=\"green\">+6%</font>. Uniti Group (NASDAQ:<a href='https://seekingalpha.com/symbol/UNIT' title='Uniti Group Inc.'>UNIT</a>) <font color=\"green\">+6%</font>. CorePoint Lodging (NYSE:<a href='https://seekingalpha.com/symbol/CPLG' title='CorePoint Lodging Inc.'>CPLG</a>) <font color=\"green\">+6%</font>. Medley Management (NYSE:<a href='https://seekingalpha.com/symbol/MDLY' title='Medley Management Inc.'>MDLY</a>) <font color=\"green\">+6%</font>.</li><li><b>Losers:</b> Marine Petroleum Trust (NASDAQ:<a href='https://seekingalpha.com/symbol/MARPS' title='Marine Petroleum Trust'>MARPS</a>) <font color=\"red\">-15%</font>. Mmtec (NASDAQ:<a href='https://seekingalpha.com/symbol/MTC' title='Mmtec, Inc.'>MTC</a>) <font color=\"red\">-13%</font>. Mesa Royalty Trust (NYSE:<a href='https://seekingalpha.com/symbol/MTR' title='Mesa Royalty Trust'>MTR</a>) <font color=\"red\">-9%</font>. Banco Macro (NYSE:<a href='https://seekingalpha.com/symbol/BMA' title='Banco Macro S.A.'>BMA</a>) <font color=\"red\">-6%</font>. Great Elm Capital Group (NASDAQ:<a href='https://seekingalpha.com/symbol/GEC' title='Great Elm Capital Group, Inc.'>GEC</a>) <font color=\"red\">-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3519378\" data-linked=\"MGI leads financial gainers; MTC and BMA among losers\" data-tweet=\"$MGI $RLGY $UNIT - MGI leads financial gainers; MTC and BMA among losers https://seekingalpha.com/news/3519378-mgi-leads-financial-gainers-mtc-and-bma-among-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3519378-mgi-leads-financial-gainers-mtc-and-bma-among-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:16 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3519375\" data-ts=\"1573754485\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3519375-astrotech-and-griffon-among-industrial-gainers-liqtech-international-and-ocean-power\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Astrotech and Griffon among Industrial gainers; LiqTech International and Ocean Power Technologies among losers</a></h4><ul><li><b>Gainers: </b>Astrotech (NASDAQ:<a href='https://seekingalpha.com/symbol/ASTC' title='Astrotech Corporation'>ASTC</a>) <font color=\"green\">+87%</font>. Griffon (NYSE:<a href='https://seekingalpha.com/symbol/GFF' title='Griffon Corporation'>GFF</a>) <font color=\"green\">+14%</font>. Charah Solutions (NYSE:<a href='https://seekingalpha.com/symbol/CHRA' title='Charah Solutions, Inc.'>CHRA</a>) <font color=\"green\">+7%</font>. Beazer Homes USA (NYSE:<a href='https://seekingalpha.com/symbol/BZH' title='Beazer Homes USA, Inc.'>BZH</a>) <font color=\"green\">+7%</font>.</li><li><b>Losers: </b>LiqTech International (NASDAQ:<a href='https://seekingalpha.com/symbol/LIQT' title='LiqTech International, Inc.'>LIQT</a>) <font color=\"red\">-37%</font>. Ocean Power Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/OPTT' title='Ocean Power Technologies, Inc.'>OPTT</a>) <font color=\"red\">-16%</font>. Avalon (NYSEMKT:<a href='https://seekingalpha.com/symbol/AWX' title='Avalon Holdings Corporation'>AWX</a>) <font color=\"red\">-15%</font>. Fuel Tech (NASDAQ:<a href='https://seekingalpha.com/symbol/FTEK' title='Fuel Tech, Inc.'>FTEK</a>) <font color=\"red\">-9%</font>. Titan International (NYSE:<a href='https://seekingalpha.com/symbol/TWI' title='Titan International, Inc.'>TWI</a>) <font color=\"red\">-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3519375\" data-linked=\"Astrotech and Griffon among Industrial gainers; LiqTech International and Ocean Power Technologies among losers\" data-tweet=\"$ASTC $GFF $CHRA - Astrotech and Griffon among Industrial gainers; LiqTech International and Ocean Power Technologies among losers https://seekingalpha.com/news/3519375-astrotech-and-griffon-among-industrial-gainers-liqtech-international-and-ocean-power?source=tweet\" data-url=\"https://seekingalpha.com/news/3519375-astrotech-and-griffon-among-industrial-gainers-liqtech-international-and-ocean-power\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:01 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3519372\" data-ts=\"1573753424\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HROW\" target=\"_blank\">HROW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3519372-harrow-health-up-22-after-improved-fundamentals-in-q3\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Harrow Health up 22% after improved fundamentals in Q3</a></h4><ul><li>Harrow Health (<a href='https://seekingalpha.com/symbol/HROW' title='Harrow Health, Inc.'>HROW</a> <font color=\"green\">+22%</font>) is up on almost a 5x surge in volume on the heels of its <a href=\"https://seekingalpha.com/news/3518895-harrow-health-eps-misses-0_21-misses-revenue\" target=\"_blank\">Q3 report</a> released after the close yesterday. Highlights:</li><li>Revenuess: $12.8M (+19%).</li><li>Net loss: ($11.5M) (-356%); loss/share: ($0.45) (-275%).</li><li>Non-GAAP EBITDA: $1.5M (+244%).</li><li><strong>Objectives by 2021</strong>: $100M run rate in annual revenue, at 70% gross margin and at least 20% operating margin.</li><li><strong>Outlook</strong>: Top line growth should continue, consistent with stated goals, as will non-GAAP EBITDA. Gross margin should continue to progress to at least 70%.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3518895-harrow-health-eps-misses-0_21-misses-revenue\" target=\"_blank\">Harrow Health EPS misses by $0.21, misses on revenue</a> (Nov. 13)</li></ul><div class=\"tiny-share-widget\" data-id=\"3519372\" data-linked=\"Harrow Health up 22% after improved fundamentals in Q3\" data-tweet=\"$HROW - Harrow Health up 22% after improved fundamentals in Q3 https://seekingalpha.com/news/3519372-harrow-health-up-22-after-improved-fundamentals-in-q3?source=tweet\" data-url=\"https://seekingalpha.com/news/3519372-harrow-health-up-22-after-improved-fundamentals-in-q3\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:43 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3519370\" data-ts=\"1573752850\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3519370-igt-opra-ping-and-sina-among-midday-movers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">IGT, OPRA, PING and SINA among midday movers</a></h4><ul><li><strong>Gainers: </strong>Astrotech Corporation (NASDAQ:<a href='https://seekingalpha.com/symbol/ASTC' title='Astrotech Corporation'>ASTC</a>) <font color=\"green\">+87%</font>.</li><li>Pier 1 Imports (NYSE:<a href='https://seekingalpha.com/symbol/PIR' title='Pier 1 Imports, Inc.'>PIR</a>) <font color=\"green\">+27%</font>.</li><li>Celsion Corporation (NASDAQ:<a href='https://seekingalpha.com/symbol/CLSN' title='Celsion Corporation'>CLSN</a>) <font color=\"green\">+22%</font>.</li><li>Harrow Health (NASDAQ:<a href='https://seekingalpha.com/symbol/HROW' title='Harrow Health, Inc.'>HROW</a>) <font color=\"green\">+21%</font>.</li><li>Alithya Group (NASDAQ:<a href='https://seekingalpha.com/symbol/ALYA' title='Alithya Group Inc.'>ALYA</a>) <font color=\"green\">+19%</font>.</li><li>International Game Technology (NYSE:<a href='https://seekingalpha.com/symbol/IGT' title='International Game Technology PLC'>IGT</a>) <font color=\"green\">+19%</font>.</li><li>Opera Limited (NASDAQ:<a href='https://seekingalpha.com/symbol/OPRA' title='Opera Limited'>OPRA</a>) <font color=\"green\">+18%</font>.</li><li>Axonics Modulation Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/AXNX' title='Axonics Modulation Technologies, Inc.'>AXNX</a>) <font color=\"green\">+17%</font>.</li><li>Precision BioSciences (NASDAQ:<a href='https://seekingalpha.com/symbol/DTIL' title='Precision BioSciences, Inc.'>DTIL</a>) <font color=\"green\">+17%</font>.</li><li>Ping Identity Holding (NYSE:<a href='https://seekingalpha.com/symbol/PING' title='Ping Identity Holding Corp.'>PING</a>) <font color=\"green\">+15%</font>.</li> <li><strong>Losers: </strong>Pacific Coast Oil Trust (NYSE:<a href='https://seekingalpha.com/symbol/ROYT' title='Pacific Coast Oil Trust'>ROYT</a>) <font color=\"red\">-74%</font>.</li><li>VistaGen Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/VTGN' title='VistaGen Therapeutics, Inc.'>VTGN</a>) <font color=\"red\">-69%</font>.</li><li>LiqTech International (NASDAQ:<a href='https://seekingalpha.com/symbol/LIQT' title='LiqTech International, Inc.'>LIQT</a>) <font color=\"red\">-37%</font>.</li><li>Leap Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/LPTX' title='Leap Therapeutics, Inc.'>LPTX</a>) <font color=\"red\">-34%</font>.</li><li>Ideanomics (NASDAQ:<a href='https://seekingalpha.com/symbol/IDEX' title='Ideanomics, Inc.'>IDEX</a>) <font color=\"red\">-28%</font>.</li><li>Westell Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/WSTL' title='Westell Technologies, Inc.'>WSTL</a>) <font color=\"red\">-27%</font>.</li><li>Jaguar Health (NASDAQ:<a href='https://seekingalpha.com/symbol/JAGX' title='Jaguar Health, Inc.'>JAGX</a>) <font color=\"red\">-27%</font>.</li><li>Ribbon Communications (NASDAQ:<a href='https://seekingalpha.com/symbol/RBBN' title='Ribbon Communications Inc.'>RBBN</a>) <font color=\"red\">-24%</font>.</li><li>electroCore (NASDAQ:<a href='https://seekingalpha.com/symbol/ECOR' title='electroCore, Inc.'>ECOR</a>) <font color=\"red\">-22%</font>.</li><li>SINA Corporation (NASDAQ:<a href='https://seekingalpha.com/symbol/SINA' title='SINA Corporation'>SINA</a>) <font color=\"red\">-18%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3519370\" data-linked=\"IGT, OPRA, PING and SINA among midday movers\" data-tweet=\"$ASTC $PIR $CLSN - IGT, OPRA, PING and SINA among midday movers https://seekingalpha.com/news/3519370-igt-opra-ping-and-sina-among-midday-movers?source=tweet\" data-url=\"https://seekingalpha.com/news/3519370-igt-opra-ping-and-sina-among-midday-movers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:34 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3519357\" data-ts=\"1573751141\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3519357-youngevity-international-ygyiplus-6-workhorse-group-among-consumer-gainers-xcel-brands-and\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Youngevity International YGYI +6%. Workhorse Group among Consumer gainers; Xcel Brands and Core Molding Technologies among losers</a></h4><ul><li><b>Gainers: </b>Youngevity International (NASDAQ:<a href='https://seekingalpha.com/symbol/YGYI' title='Youngevity International, Inc.'>YGYI</a>) <font color=\"green\">+6%</font>. Workhorse Group (NASDAQ:<a href='https://seekingalpha.com/symbol/WKHS' title='Workhorse Group Inc.'>WKHS</a>) <font color=\"green\">+6%</font>. Purple Innovation (NASDAQ:<a href='https://seekingalpha.com/symbol/PRPL' title='Purple Innovation, Inc.'>PRPL</a>) <font color=\"green\">+6%</font>. Meritor (NYSE:<a href='https://seekingalpha.com/symbol/MTOR' title='Meritor, Inc.'>MTOR</a>) <font color=\"green\">+6%</font>.</li><li><b>Losers: </b>Xcel Brands (NASDAQ:<a href='https://seekingalpha.com/symbol/XELB' title='Xcel Brands, Inc.'>XELB</a>) <font color=\"red\">-17%</font>. Core Molding Technologies (NYSEMKT:<a href='https://seekingalpha.com/symbol/CMT' title='Core Molding Technologies, Inc.'>CMT</a>) <font color=\"red\">-12%</font>. Iconix Brand Group (NASDAQ:<a href='https://seekingalpha.com/symbol/ICON' title='Iconix Brand Group, Inc.'>ICON</a>) <font color=\"red\">-9%</font>. New Age Beverages (NASDAQ:<a href='https://seekingalpha.com/symbol/NBEV' title='New Age Beverages Corporation'>NBEV</a>) <font color=\"red\">-7%</font>. NIO (NYSE:<a href='https://seekingalpha.com/symbol/NIO' title='NIO Inc.'>NIO</a>) <font color=\"red\">-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3519357\" data-linked=\"Youngevity International YGYI +6%. Workhorse Group among Consumer gainers; Xcel Brands and Core Molding Technologies among losers\" data-tweet=\"$YGYI $WKHS $PRPL - Youngevity International YGYI +6%. Workhorse Group among Consumer gainers; Xcel Brands and Core Molding Technologies among losers https://seekingalpha.com/news/3519357-youngevity-international-ygyiplus-6-workhorse-group-among-consumer-gainers-xcel-brands-and?source=tweet\" data-url=\"https://seekingalpha.com/news/3519357-youngevity-international-ygyiplus-6-workhorse-group-among-consumer-gainers-xcel-brands-and\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:05 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3519355\" data-ts=\"1573750726\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AZRX\" target=\"_blank\">AZRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3519355-azurrx-up-31-on-stock-purchase-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AzurRx up 31% on stock purchase deal</a></h4><ul><li>Thinly traded nano cap AzurRx BioPharma (<a href='https://seekingalpha.com/symbol/AZRX' title='AzurRx BioPharma, Inc.'>AZRX</a> <font color=\"green\">+31.1%</font>) is up on 65% higher volume, albeit on turnover of only 516K shares, on the heels of its $15M common stock purchase <a href=\"https://seekingalpha.com/pr/17699220-azurrx-biopharma-inc-announces-equity-purchase-agreement-15-million-lincoln-park-capital-fund\" target=\"_blank\">agreement </a>with Lincoln Park Capital Fund, LLC.</li><li>Under the terms of the deal, the company will have the right to sell up to $15M of stock to the investor over a 30-month period, subject to conditions, at its discretion.</li></ul><div class=\"tiny-share-widget\" data-id=\"3519355\" data-linked=\"AzurRx up 31% on stock purchase deal\" data-tweet=\"$AZRX - AzurRx up 31% on stock purchase deal https://seekingalpha.com/news/3519355-azurrx-up-31-on-stock-purchase-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3519355-azurrx-up-31-on-stock-purchase-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:58 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3519343\" data-ts=\"1573749665\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RVVTF\" target=\"_blank\">RVVTF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3519343-revives-cannabis-jv-fails-to-excite-investors-shares-down-26\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Revive&#39;s cannabis JV fails to excite investors, shares down 26%</a></h4><ul><li>Thinly traded nano cap Revive Therapeutics Ltd. (<a href='https://seekingalpha.com/symbol/RVVTF' title='Revive Therapeutics Ltd.'>OTCQB:RVVTF</a> <font color=\"red\">-25.7%</font>) is down on more than a 9x surge in volume, albeit on turnover of only 46K shares, following its <a href=\"https://seekingalpha.com/pr/17698944-revive-therapeutics-announces-joint-venture-herman-holdings-production-cannabis-derivative\" target=\"_blank\">announced </a>joint venture &#40;JV&#41; with Herman Holdings Ltd. aimed at selling cannabis derivative products in the Canadian recreational market.</li><li>Specifically, the JV will formulate and develop all-natural gummies and solventless rosin vape cartridges with pesticide-free, non-irradiated flower supplied by Richmond Cannabis Co. It will also manufacture white-labeled products for other cannabis companies for domestic use.</li><li>Financial terms are not disclosed.</li></ul><div class=\"tiny-share-widget\" data-id=\"3519343\" data-linked=\"Revive&#39;s cannabis JV fails to excite investors, shares down 26%\" data-tweet=\"$RVVTF - Revive&#39;s cannabis JV fails to excite investors, shares down 26% https://seekingalpha.com/news/3519343-revives-cannabis-jv-fails-to-excite-investors-shares-down-26?source=tweet\" data-url=\"https://seekingalpha.com/news/3519343-revives-cannabis-jv-fails-to-excite-investors-shares-down-26\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:41 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3519340\" data-ts=\"1573748908\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JAGX\" target=\"_blank\">JAGX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3519340-jaguar-health-down-21-on-mytesi-trial-continuation\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Jaguar Health down 21% on Mytesi trial continuation</a></h4><ul><li>Investors appear disappointed that they did not hear more <a href=\"https://seekingalpha.com/pr/17699219-jaguar-health-announces-interim-analysis-requirement-met-phase-2-halt-d-study-evaluating\" target=\"_blank\">positive news</a> from Jaguar Health (<a href='https://seekingalpha.com/symbol/JAGX' title='Jaguar Health, Inc.'>JAGX</a> <font color=\"red\">-20.7%</font>) about an investigator-initiated Phase 2 clinical trial, <a href=\"https://clinicaltrials.gov/ct2/show/NCT02910219?titles=halt-d&amp;phase=1&amp;draw=2&amp;rank=1\" target=\"_blank\">HALT-D</a>, evaluating the effectiveness of Mytesi (crofelemer) in relieving diarrhea in HER2-positive breast cancer patients undergoing chemotherapy.</li><li>Based on a review from Georgetown University's Data Safety Monitoring Committee, the study will continue unchanged to completion. It is currently 85% enrolled.</li><li>The company is planning a Phase 3 trial evaluating Mytesi for chemo-related diarrhea. It says results from HALT-D are not required for FDA approval, but the data could inform the late-stage study.</li></ul><div class=\"tiny-share-widget\" data-id=\"3519340\" data-linked=\"Jaguar Health down 21% on Mytesi trial continuation\" data-tweet=\"$JAGX - Jaguar Health down 21% on Mytesi trial continuation https://seekingalpha.com/news/3519340-jaguar-health-down-21-on-mytesi-trial-continuation?source=tweet\" data-url=\"https://seekingalpha.com/news/3519340-jaguar-health-down-21-on-mytesi-trial-continuation\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:28 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3519338\" data-ts=\"1573748688\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3519338-kadmon-holdings-leads-healthcare-gainers-electrocore-and-jaguar-health-among-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Kadmon Holdings leads healthcare gainers, electroCore and Jaguar Health among losers</a></h4><ul><li><b>Gainers:</b> Kadmon Holdings (NYSE:<a href='https://seekingalpha.com/symbol/KDMN' title='Kadmon Holdings, Inc.'>KDMN</a>) <font color=\"green\">+17%</font>. Harrow Health (NASDAQ:<a href='https://seekingalpha.com/symbol/HROW' title='Harrow Health, Inc.'>HROW</a>) <font color=\"green\">+15%</font>. Enochian Biosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/ENOB' title='Enochian Biosciences Inc.'>ENOB</a>) <font color=\"green\">+14%</font>. Exicure (NASDAQ:<a href='https://seekingalpha.com/symbol/XCUR' title='Exicure, Inc.'>XCUR</a>) <font color=\"green\">+14%</font>. Axonics Modulation Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/AXNX' title='Axonics Modulation Technologies, Inc.'>AXNX</a>) <font color=\"green\">+13%</font>.</li><li><b>Losers:</b> VistaGen Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/VTGN' title='VistaGen Therapeutics, Inc.'>VTGN</a>) <font color=\"red\">-67%</font>. electroCore (NASDAQ:<a href='https://seekingalpha.com/symbol/ECOR' title='electroCore, Inc.'>ECOR</a>) <font color=\"red\">-21%</font>. Jaguar Health (NASDAQ:<a href='https://seekingalpha.com/symbol/JAGX' title='Jaguar Health, Inc.'>JAGX</a>) <font color=\"red\">-20%</font>. Canopy Growth (NYSE:<a href='https://seekingalpha.com/symbol/CGC' title='Canopy Growth Corporation'>CGC</a>) <font color=\"red\">-17%</font>. Fulgent Genetics (NASDAQ:<a href='https://seekingalpha.com/symbol/FLGT' title='Fulgent Genetics, Inc.'>FLGT</a>) <font color=\"red\">-17%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3519338\" data-linked=\"Kadmon Holdings leads healthcare gainers, electroCore and Jaguar Health among losers\" data-tweet=\"$KDMN $HROW $ENOB - Kadmon Holdings leads healthcare gainers, electroCore and Jaguar Health among losers https://seekingalpha.com/news/3519338-kadmon-holdings-leads-healthcare-gainers-electrocore-and-jaguar-health-among-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3519338-kadmon-holdings-leads-healthcare-gainers-electrocore-and-jaguar-health-among-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:24 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3519336\" data-ts=\"1573748290\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GDEN\" target=\"_blank\">GDEN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3519336-golden-entertainmentplus-5-after-insider-buying-action\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Golden Entertainment +5% after insider buying action</a></h4><ul> <li>Golden Entertainment (NASDAQ:<a href='https://seekingalpha.com/symbol/GDEN' title='Golden Entertainment, Inc.'>GDEN</a>) director Anthony Marnell discloses he picked up 64K shares in the casino company at $16.85 per share.</li> <li>Marnell is a longtime casino owner in Nevada, and his company still owns and operates the Nugget Casino Resort in Sparks, Nevada.</li> <li>Shares of GDEN are <font color=\"green\">up 4.71%</font> to $17.77 and traded as high as $18.27 earlier in the session.</li> <li><a href=\"https://seekingalpha.com/filing/4699243\" target=\"_blank\">SEC Form 4</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3519336\" data-linked=\"Golden Entertainment +5% after insider buying action\" data-tweet=\"$GDEN - Golden Entertainment +5% after insider buying action https://seekingalpha.com/news/3519336-golden-entertainmentplus-5-after-insider-buying-action?source=tweet\" data-url=\"https://seekingalpha.com/news/3519336-golden-entertainmentplus-5-after-insider-buying-action\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:18 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3519334\" data-ts=\"1573747840\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3519334-viacom-up-after-q4-profits-top-views\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Viacom up after Q4 profits top views</a></h4><ul>   <li>Viacom is higher (<a href='https://seekingalpha.com/symbol/VIA' title='Viacom Inc.'>VIA</a> <font color=\"green\">+3.2%</font>, <a href='https://seekingalpha.com/symbol/VIAB' title='Viacom Inc.'>VIAB</a> <font color=\"green\">+2.4%</font>) after it turned in better-than-expected profit in its <a href=\"https://seekingalpha.com/news/3519125-viacom-eps-beats-0_03-misses-revenue\" target=\"_blank\">fourth-quarter earnings</a>.</li>    <li>Revenues overall dipped 1.7% to $3.43B; revenues at Paramount fell by double-digits, but adjusted operating income there was up 42% to $54M.</li>    <li>And in Media Networks, domestic advertising achieved its first full year of growth in six years after rising 6% for the quarter. Affiliate revenue growth was 1%.</li>    <li>Overall, operating income fell 18% to $530M. Adjusted net earnings from continuing operations dropped 20%, to $321M.</li>    <li>Revenue by segment: Filmed Entertainment, $851M (down 14%); Media Networks, $2.61B (up 4%).</li>    <li><a href=\"https://seekingalpha.com/article/4306560-viacom-inc-2019-q4-results-earnings-call-presentation\" target=\"_blank\">Earnings call presentation</a></li>    <li><a href=\"https://seekingalpha.com/pr/17698951-viacom-reports-fourth-quarter-full-year-results\" target=\"_blank\">Press release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3519334\" data-linked=\"Viacom up after Q4 profits top views\" data-tweet=\"$VIA $VIAB - Viacom up after Q4 profits top views https://seekingalpha.com/news/3519334-viacom-up-after-q4-profits-top-views?source=tweet\" data-url=\"https://seekingalpha.com/news/3519334-viacom-up-after-q4-profits-top-views\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:10 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3519331\" data-ts=\"1573747608\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VTGN\" target=\"_blank\">VTGN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3519331-vistagens-avminus-101-flunks-mdd-study-shares-down-67\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">VistaGen&#39;s AV-101 flunks MDD study; shares down 67%</a></h4><ul><li>Thinly traded nano cap VistaGen Therapeutics (<a href='https://seekingalpha.com/symbol/VTGN' title='VistaGen Therapeutics, Inc.'>VTGN</a> <font color=\"red\">-67%</font>) craters on more than a 9x surge in volume after AV-101 <a href=\"https://seekingalpha.com/pr/17699060-vistagen-reports-topline-phase-2-results-avminus-101-adjunctive-treatment-major-depressive\" target=\"_blank\">failed to separate from placebo</a> in a Phase 2 clinical trial, <a href=\"https://clinicaltrials.gov/ct2/show/NCT03078322?intr=AV-101&amp;lead=vistagen&amp;phase=1\" target=\"_blank\">ELEVATE</a>, evaluating the candidate for the adjunctive treatment of major depressive disorder.</li><li>Specifically, treatment with AV-101 failed to differentiate from control as measured by the change from baseline in a scale called MADRS-10.</li><li>CEO Shawn Singh says the problem could have been insufficient transport of AV-101 across the blood-brain barrier or subsequent inadequate concentrations of its active metabolite, adding that data analyses are continuing.</li><li>In May, AV-101 as monotherapy <a href=\"https://seekingalpha.com/news/3458065-vistagens-avminus-101-flunks-mid-stage-depression-study-shares-45-percent\" target=\"_blank\">failed a mid-stage study</a> in treatment-resistant depression.</li><li>AV-101 is an NMDA receptor glycine B antagonist.</li></ul><div class=\"tiny-share-widget\" data-id=\"3519331\" data-linked=\"VistaGen&#39;s AV-101 flunks MDD study; shares down 67%\" data-tweet=\"$VTGN - VistaGen&#39;s AV-101 flunks MDD study; shares down 67% https://seekingalpha.com/news/3519331-vistagens-avminus-101-flunks-mdd-study-shares-down-67?source=tweet\" data-url=\"https://seekingalpha.com/news/3519331-vistagens-avminus-101-flunks-mdd-study-shares-down-67\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:06 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3519329\" data-ts=\"1573747324\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3519329-oil-inventories-rise-bit-expected\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Oil inventories rise a bit more than expected</a></h4><ul><li><a href=\"http://ir.eia.gov/wpsr/wpsrsummary.pdf\" target=\"_blank\">EIA Petroleum Inventories:</a> Crude <strong>+2.2M</strong> barrels vs. +1.6M consensus, +7.9M last week.</li><li>Gasoline <strong>+1.9M</strong> barrels vs. -1.2M consensus, -2.8M last week.</li><li>Distillates<strong> -2.5M</strong> barrels vs. -0.9M consensus, -0.6M last week.</li><li>Futures <font color=\"green\">+0.96%</font> to $57.69.</li><li>ETFs: <a href='https://seekingalpha.com/symbol/USO' title='The United States Oil ETF, LP'>USO</a>, <a href='https://seekingalpha.com/symbol/OIL' title='iPath S&P GSCI Crude Oil Total Return Index ETN'>OIL</a>, <a href='https://seekingalpha.com/symbol/UCO' title='ProShares Trust II - ProShares Ultra Bloomberg Crude Oil'>UCO</a>, <a href='https://seekingalpha.com/symbol/SCO' title='ProShares UltraShort Bloomberg Crude Oil ETF'>SCO</a>, <a href='https://seekingalpha.com/symbol/BNO' title='United States Brent Oil Fund, LP'>BNO</a>, <a href='https://seekingalpha.com/symbol/DTO' title='DB Crude Oil Double Short ETN'>DTO</a>, <a href='https://seekingalpha.com/symbol/DBO' title='Invesco DB Oil ETF'>DBO</a>, <a href='https://seekingalpha.com/symbol/USL' title='United States 12 Month Oil Fund, LP'>USL</a>, <a href='https://seekingalpha.com/symbol/SZO' title='DB Crude Oil Short ETN'>SZO</a>, <a href='https://seekingalpha.com/symbol/OLO' title='DB Crude Oil Long ETN'>OLO</a>, <a href='https://seekingalpha.com/symbol/OLEM' title='iPath Pure Beta Crude Oil ETN'>OLEM</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3519329\" data-linked=\"Oil inventories rise a bit more than expected\" data-tweet=\"$USO $OIL $UCO - Oil inventories rise a bit more than expected https://seekingalpha.com/news/3519329-oil-inventories-rise-bit-expected?source=tweet\" data-url=\"https://seekingalpha.com/news/3519329-oil-inventories-rise-bit-expected\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:02 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>94&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3519328\" data-ts=\"1573747083\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UBER\" target=\"_blank\">UBER</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3519328-uber-owes-nj-650m-in-employment-taxes\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Uber owes NJ $650M in employment taxes</a></h4><ul><li>New Jersey's labor department <a href=\"https://news.bloomberglaw.com/daily-labor-report/uber-hit-with-650-million-employment-tax-bill-in-new-jersey?context=search&amp;index=0&amp;campaign=03510C0E-06EF-11EA-9043-88E84F017A06&amp;utm_medium=lawdesk&amp;utm_source=twitter\" target=\"_blank\">says</a> Uber (NYSE:<a href='https://seekingalpha.com/symbol/UBER' title='Uber Technologies, Inc.'>UBER</a>) owes the state unemployment and disability insurance taxes for improperly classifying its drivers as independent contractors.</li><li>Uber and subsidiary Rasier were assessed $523M in past-due taxes over the last four years. The company also owes as much as $119M in interest and penalties on the unpaid amounts.</li><li>The determination only relates to unemployment and disability insurance, but could lead to requirements for minimum driver pay and overtime requirements.</li><li>Source: Letters sent to the companies, obtained by Bloomberg Law.</li><li>Uber shares are <font color=\"red\">down 1.9%</font> to $26.21. Competitor Lyft (<a href='https://seekingalpha.com/symbol/LYFT' title='Lyft, Inc.'>LYFT</a> <font color='red'>-2.7%</font>) is also down after the news.</li></ul><div class=\"tiny-share-widget\" data-id=\"3519328\" data-linked=\"Uber owes NJ $650M in employment taxes\" data-tweet=\"$UBER $UBER $LYFT - Uber owes NJ $650M in employment taxes https://seekingalpha.com/news/3519328-uber-owes-nj-650m-in-employment-taxes?source=tweet\" data-url=\"https://seekingalpha.com/news/3519328-uber-owes-nj-650m-in-employment-taxes\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:58 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>62&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3519323\" data-ts=\"1573745803\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CGC\" target=\"_blank\">CGC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3519323-canopy-growth-down-18-realism-cannabis-market-builds\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Canopy Growth down 18% as realism with cannabis market builds</a></h4><ul><li>Canopy Growth (<a href='https://seekingalpha.com/symbol/CGC' title='Canopy Growth Corporation'>CGC</a> <font color=\"red\">-17.7%</font>), considered by many as the leader in the overhyped cannabis sector, slumps on almost double normal volume after its <a href=\"https://seekingalpha.com/pr/17698887-canopy-growth-reports-second-quarter-fiscal-2020-financial-results\" target=\"_blank\">fiscal Q2 report</a> released this morning that represented yet another example of investors' unrealistic near-term valuation views.</li><li><a href=\"https://seekingalpha.com/news/3519163-canopy-growth-6-percent-premarket-fq2-miss-higher-cash-burn\" target=\"_blank\">Net revenue</a> was C$76.6M, up 229% from a year ago but down 15% from the previous quarter, a clear sign of headwinds principally due to too many producers who have ramped up capacity chasing too few customers.</li><li>Operating expenses continued to climb, up 48% from a year ago and up 15% sequentially. Non-GAAP EBITDA was solidly negative (C$155.7M) as was cash flow ops.</li><li>Inventory was C$461.8M, up 17% from Q1, another signal, albeit preliminary, of a backup in demand.</li><li>Cannabis oil and softgel sales were down 80% from Q1.</li><li>Related tickers: Aurora Cannabis (<a href='https://seekingalpha.com/symbol/ACB' title='Aurora Cannabis Inc.'>ACB</a> <font color=\"red\">-12.1%</font>), Cronos Group (<a href='https://seekingalpha.com/symbol/CRON' title='Cronos Group Inc.'>CRON</a> <font color=\"red\">-6.6%</font>), Tilray (<a href='https://seekingalpha.com/symbol/TLRY' title='Tilray, Inc.'>TLRY</a> <font color=\"red\">-4.4%</font>), Aphria (<a href='https://seekingalpha.com/symbol/APHA' title='Aphria Inc.'>APHA</a> <font color=\"red\">-8.1%</font>), Horizons Marijuana Life Sciences Index ETF (<a href='https://seekingalpha.com/symbol/HMLSF' title='Horizons Marijuana Life Sciences Index ETF'>HMLSF</a> <font color=\"red\">-5.4%</font>)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3519112-canopy-growth-eps-misses-c-0_73-misses-revenue\" target=\"_blank\">Canopy Growth EPS misses by C$0.73, misses on revenue</a> (Nov. 14)</li></ul><div class=\"tiny-share-widget\" data-id=\"3519323\" data-linked=\"Canopy Growth down 18% as realism with cannabis market builds\" data-tweet=\"$CGC $ACB $CRON - Canopy Growth down 18% as realism with cannabis market builds https://seekingalpha.com/news/3519323-canopy-growth-down-18-realism-cannabis-market-builds?source=tweet\" data-url=\"https://seekingalpha.com/news/3519323-canopy-growth-down-18-realism-cannabis-market-builds\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:36 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>195&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3519319\" data-ts=\"1573745532\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SAFM\" target=\"_blank\">SAFM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3519319-baml-tags-sanderson-farms-two-notch-upgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BAML tags Sanderson Farms with two-notch upgrade</a></h4><ul> <li>Bank of America Merrill Lynch says it's wasting no time in shifting its outlook on Sanderson Farms (<a href='https://seekingalpha.com/symbol/SAFM' title='Sanderson Farms, Inc.'>SAFM</a> <font color=\"green\">+3.4%</font>) after China lifted its poultry import ban.</li> <li>\"We expect all US chicken processors to benefit including SAFM, TSN and PPC; however, we believe SAFM will see the most incremental benefit as the company now has access to shipping chicken feet/paws and wing tips to China where it has not shipped since 2015 (~$70mm of annual EBIT). As a result we raise our CY20 EBITDA estimates from $354mm to $425mm and our valuation multiple from 8.3x to 9.3x,\" updates the firm.</li> <li>BAML hikes Sanderson Farms two notches to a Buy rating from Underperform.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3519251-china-lifts-u-s-poultry-import-restrictions\" target=\"_blank\">China lifts U.S. poultry import restrictions</a> (Nov. 14)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3519319\" data-linked=\"BAML tags Sanderson Farms with two-notch upgrade\" data-tweet=\"$SAFM - BAML tags Sanderson Farms with two-notch upgrade https://seekingalpha.com/news/3519319-baml-tags-sanderson-farms-two-notch-upgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3519319-baml-tags-sanderson-farms-two-notch-upgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:32 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3519318\" data-ts=\"1573745501\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3519318-natural-gas-inventory-build-misses-consensus\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Natural gas inventory build misses consensus</a></h4><ul><li><a href=\"http://ir.eia.gov/ngs/ngs.html\" target=\"_blank\">EIA Natural Gas Inventory:</a> <strong>+3 Bcf</strong> vs. +45 Bcf consensus, +34 Bcf last week.</li><li>Futures <font color=\"green\">+2.58%</font> to $2.667.</li><li>ETFs:<a href='https://seekingalpha.com/symbol/UNG' title='The United States Natural Gas ETF, LP'>UNG</a>, <a href='https://seekingalpha.com/symbol/DGAZ' title='VelocityShares 3x Inverse Natural Gas ETN'>DGAZ</a>, <a href='https://seekingalpha.com/symbol/UGAZ' title='VelocityShares 3x Long Natural Gas ETN'>UGAZ</a>, <a href='https://seekingalpha.com/symbol/BOIL' title='ProShares Trust II - ProShares Ultra Bloomberg Natural Gas'>BOIL</a>, <a href='https://seekingalpha.com/symbol/KOLD' title='ProShares Trust II - ProShares UltraShort Bloomberg Natural Gas'>KOLD</a>, <a href='https://seekingalpha.com/symbol/UNL' title='United States 12 Month Natural Gas Fund, LP'>UNL</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3519318\" data-linked=\"Natural gas inventory build misses consensus\" data-tweet=\"$UNG $DGAZ $UGAZ - Natural gas inventory build misses consensus https://seekingalpha.com/news/3519318-natural-gas-inventory-build-misses-consensus?source=tweet\" data-url=\"https://seekingalpha.com/news/3519318-natural-gas-inventory-build-misses-consensus\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:31 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>90&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3519314\" data-ts=\"1573744879\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CTRA\" target=\"_blank\">CTRA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3519314-contura-energyminus-38-after-q3-earnings-miss-coal-shipments-guidance-cut\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Contura Energy -38% after Q3 earnings miss, coal shipments guidance cut</a></h4><ul><li>Contura Energy (<a href='https://seekingalpha.com/symbol/CTRA' title='Contura Energy, Inc.'>CTRA</a> <font color=\"red\">-38.6%</font>) plunges to all-time lows after reporting a massive <a href=\"https://seekingalpha.com/news/3519170-contura-energy-eps-2_29\" target=\"_blank\">Q3 loss</a> and weaker than expected growth in revenues; Q3 adjusted EBITDA was $40M, compared with $141M in Q2 and $39M in the year-ago quarter.</li><li>CTRA cites the worst global metallurgical coal market conditions in three years and weaker than expected performance in thermal cost for the disappointing results.</li><li>The company says it has suspended future share repurchase activities due to continued softness in the met coal markets and accelerated cash outflows due to the PRB transaction.</li><li>CTRA cuts full-year coal shipments guidance to 23.2M-24.6M tons from its previous outlook of 23.9M-25.6M tons; CAPP met coal guidance is lowered to 12.4M-13M tons from 12.8M-13.7M tons, citing softer market conditions, especially in Europe and South America, and NAPP shipments are now seen at 6.5M-6.9M tons vs. 6.8M-7.2M tons previously, while guidance for CAPP thermal coal shipments remains unchanged at 4.3M-4.7M tons.</li><li>For FY 2020, CTRA expects CAPP met coal shipments to improve to 12.7M-13.3M tons, while CAPP thermal volume guidance is lowered to 3.4M-4M tons; NAPP shipments also are forecast to come in lower in 2020 at 6M-6.8M tons as the company prepares to move into a new district in 2021 with longer panels and fewer longwall moves, which should increase productivity and efficiency starting in 2022.</li></ul><div class=\"tiny-share-widget\" data-id=\"3519314\" data-linked=\"Contura Energy -38% after Q3 earnings miss, coal shipments guidance cut\" data-tweet=\"$CTRA - Contura Energy -38% after Q3 earnings miss, coal shipments guidance cut https://seekingalpha.com/news/3519314-contura-energyminus-38-after-q3-earnings-miss-coal-shipments-guidance-cut?source=tweet\" data-url=\"https://seekingalpha.com/news/3519314-contura-energyminus-38-after-q3-earnings-miss-coal-shipments-guidance-cut\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:21 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3519313\" data-ts=\"1573744711\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SPLK\" target=\"_blank\">SPLK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3519313-cleveland-research-hits-splunk-sidelines-splkminus-5\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cleveland Research hits Splunk sidelines; SPLK -5%</a></h4><ul><li>Cleveland Research cuts Splunk (NASDAQ:<a href='https://seekingalpha.com/symbol/SPLK' title='Splunk Inc.'>SPLK</a>) to Neutral, citing partner discussions suggesting expectations for slower growth.</li><li>The research firm is more cautious about the next 12-18 months due to the talks, customer spending sensitivity, and competitor evaluations.</li><li>Splunk<font color=\"red\"> plunges 5.3%</font> to $118.06.</li></ul><div class=\"tiny-share-widget\" data-id=\"3519313\" data-linked=\"Cleveland Research hits Splunk sidelines; SPLK -5%\" data-tweet=\"$SPLK - Cleveland Research hits Splunk sidelines; SPLK -5% https://seekingalpha.com/news/3519313-cleveland-research-hits-splunk-sidelines-splkminus-5?source=tweet\" data-url=\"https://seekingalpha.com/news/3519313-cleveland-research-hits-splunk-sidelines-splkminus-5\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:18 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3519312\" data-ts=\"1573744697\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DDS\" target=\"_blank\">DDS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3519312-dillardsplus-17-earnings-put-squeeze-on\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Dillard&#39;s +17% as earnings put the squeeze on</a></h4><ul> <li>Shares of Dillard's (NYSE:<a href='https://seekingalpha.com/symbol/DDS' title='Dillard&#39;s, Inc.'>DDS</a>) rally after the department store operator showed margin improvement in Q3. Dillard's also lowered its full-year capital expenditure forecast to $115M from a prior view for $125M.</li> <li>DDS is <font color=\"green\">up 17.19%</font> and traded as high as $84.47 earlier in the session. The big jump in share price coincides with a high level of short interest on the name.</li> <li>Previously: <a href=\"https://seekingalpha.com/news/3519177-dillards-tightens-q3\" target=\"_blank\">Dillard's tightens up in Q3</a> (Nov. 14)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3519312\" data-linked=\"Dillard&#39;s +17% as earnings put the squeeze on\" data-tweet=\"$DDS - Dillard&#39;s +17% as earnings put the squeeze on https://seekingalpha.com/news/3519312-dillardsplus-17-earnings-put-squeeze-on?source=tweet\" data-url=\"https://seekingalpha.com/news/3519312-dillardsplus-17-earnings-put-squeeze-on\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:18 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3519304\" data-ts=\"1573743655\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3519304-ciscominus-7_4-forecast-spurs-target-cuts\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cisco -7.4% as forecast spurs target cuts</a></h4><ul>   <li>Cisco Systems (NASDAQ:<a href='https://seekingalpha.com/symbol/CSCO' title='Cisco Systems, Inc.'>CSCO</a>) is <font color=\"red\">down 7.4%</font> out of today's market open, following a <a href=\"https://seekingalpha.com/news/3518915-cisco-minus-4_7-percent-q2-forecast-disappoints\" target=\"_blank\">Q1 earnings report</a> that featured surprising light sales guidance for the current quarter, spurring some target cuts.</li>    <li>Citi trimmed its price target to $55 from $57, but is sticking with its Buy rating.</li>    <li>Barclays rates it Equal Weight and cut its target to $47 from $51; that now implies 4.7% upside after today's drop (it implied 3% downside from yesterday's close).</li>    <li>Cisco's forecast has some investors concerned about corporate spending in the area. Peers and rivals in the space are lower today in a generally flat market: Nokia (NYSE:<a href='https://seekingalpha.com/symbol/NOK' title='Nokia Corporation'>NOK</a>) is <font color=\"red\">off 2.3%</font> while Ericsson (NASDAQ:<a href='https://seekingalpha.com/symbol/ERIC' title='Telefonaktiebolaget LM Ericsson &#40;publ&#41;'>ERIC</a>) is <font color=\"red\">down just 0.6%</font>. Juniper Networks (NYSE:<a href='https://seekingalpha.com/symbol/JNPR' title='Juniper Networks, Inc.'>JNPR</a>) is <font color=\"red\">down 1.6%</font> and Arista Networks (NYSE:<a href='https://seekingalpha.com/symbol/ANET' title='Arista Networks, Inc.'>ANET</a>) is <font color=\"red\">down just 0.4%</font>.</li>     <li><a href=\"https://seekingalpha.com/article/4306457-cisco-systems-inc-csco-ceo-chuck-robbins-q1-2020-results-earnings-call-transcript\" target=\"_blank\">Earnings call transcript</a></li>   </ul><div class=\"tiny-share-widget\" data-id=\"3519304\" data-linked=\"Cisco -7.4% as forecast spurs target cuts\" data-tweet=\"$CSCO $NOK $ERIC - Cisco -7.4% as forecast spurs target cuts https://seekingalpha.com/news/3519304-ciscominus-7_4-forecast-spurs-target-cuts?source=tweet\" data-url=\"https://seekingalpha.com/news/3519304-ciscominus-7_4-forecast-spurs-target-cuts\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:00 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>70&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3519287\" data-ts=\"1573742099\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LPCN\" target=\"_blank\">LPCN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3519287-lipocine-prices-equity-offering-shares-down-35\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Lipocine prices equity offering; shares down 35%</a></h4><ul><li>Lipocine (<a href='https://seekingalpha.com/symbol/LPCN' title='Lipocine Inc.'>LPCN</a> <font color=\"red\">-34.6%</font>) prices its <a href=\"https://seekingalpha.com/pr/17699578-lipocine-announces-pricing-public-offering-common-stock-warrants\" target=\"_blank\">public offering</a> of 10.45M Class A Units at $0.50 and 1.55M Class B Units at $0.4999.</li><li>Each Class A Unit consists of one common share and (unspecified) common warrants to purchase common shares.</li><li>Each Class B Unit consists of pre-funded warrants and common warrants to purchase common shares.</li></ul><div class=\"tiny-share-widget\" data-id=\"3519287\" data-linked=\"Lipocine prices equity offering; shares down 35%\" data-tweet=\"$LPCN - Lipocine prices equity offering; shares down 35% https://seekingalpha.com/news/3519287-lipocine-prices-equity-offering-shares-down-35?source=tweet\" data-url=\"https://seekingalpha.com/news/3519287-lipocine-prices-equity-offering-shares-down-35\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:34 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3519275\" data-ts=\"1573741311\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3519275-wb-cgc-among-premarket-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">WB, CGC among premarket losers</a></h4><ul><li>VistaGen Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/VTGN' title='VistaGen Therapeutics, Inc.'>VTGN</a>) <font color=\"red\">-67%</font> on reporting <a href=\"https://seekingalpha.com/pr/17699060-vistagen-reports-topline-phase-2-results-avminus-101-adjunctive-treatment-major-depressive\" target=\"_blank\">Phase 2 results for AV-101</a> as a treatment of major depressive disorder.</li><li>Pacific Coast Oil Trust (NYSE:<a href='https://seekingalpha.com/symbol/ROYT' title='Pacific Coast Oil Trust'>ROYT</a>) <font color=\"red\">-68%</font> after issuing <a href=\"https://seekingalpha.com/news/3519043-pacific-coast-royal-trust-issues-termination-warning\" target=\"_blank\">termination warning</a>.</li><li>Ideanomics (NASDAQ:<a href='https://seekingalpha.com/symbol/IDEX' title='Ideanomics, Inc.'>IDEX</a>) <font color=\"red\">-36%</font> on <a href=\"https://seekingalpha.com/news/3519222-ideanomics-reports-q3-results\" target=\"_blank\">Q3 earnings</a>.</li><li>LiqTech International (NASDAQ:<a href='https://seekingalpha.com/symbol/LIQT' title='LiqTech International, Inc.'>LIQT</a>) <font color=\"red\">-20%</font> on <a href=\"https://seekingalpha.com/news/3519219-liqtech-eps-misses-0_01-misses-revenue\" target=\"_blank\">Q3 earnings</a>.</li><li>Fulgent Genetics (NASDAQ:<a href='https://seekingalpha.com/symbol/FLGT' title='Fulgent Genetics, Inc.'>FLGT</a>) <font color=\"red\">-15%</font> on <a href=\"https://seekingalpha.com/news/3519191-fulgent-12-percent-premarket-pricing-equity-offering\" target=\"_blank\">pricing</a> equity offering.</li><li>Xunlei (NASDAQ:<a href='https://seekingalpha.com/symbol/XNET' title='Xunlei Limited'>XNET</a>) <font color=\"red\">-12%</font> on <a href=\"https://seekingalpha.com/news/3519077-xunlei-reports-q3-results\" target=\"_blank\">Q3 earnings</a>.</li><li>Precipio (NASDAQ:<a href='https://seekingalpha.com/symbol/PRPO' title='Precipio, Inc.'>PRPO</a>) <font color=\"red\">-12%</font>. on <a href=\"https://seekingalpha.com/news/3519004-precipio-eps-beats-0_08-misses-revenue\" target=\"_blank\">Q3 earnings</a>.</li><li>New Age Beverages (NASDAQ:<a href='https://seekingalpha.com/symbol/NBEV' title='New Age Beverages Corporation'>NBEV</a>) <font color=\"red\">-11%</font> on <a href=\"https://seekingalpha.com/news/3519092-new-age-beverages-eps-misses-0_10-misses-revenue\" target=\"_blank\">Q3 earnings</a>.</li><li>Weibo (NASDAQ:<a href='https://seekingalpha.com/symbol/WB' title='Weibo Corporation'>WB</a>) <font color=\"red\">-11%</font> on <a href=\"https://seekingalpha.com/news/3519074-weibo-eps-beats-0_04-misses-revenue\" target=\"_blank\">Q3 earnings</a>.</li><li>Avita Medical (NASDAQ:<a href='https://seekingalpha.com/symbol/RCEL' title='Avita Medical Limited'>RCEL</a>) <font color=\"red\">-9%</font>.</li><li>Canopy Growth (NYSE:<a href='https://seekingalpha.com/symbol/CGC' title='Canopy Growth Corporation'>CGC</a>) <font color=\"red\">-9%</font> on <a href=\"https://seekingalpha.com/news/3519112-canopy-growth-eps-misses-c-0_73-misses-revenue\" target=\"_blank\">Q3 earnings</a>.</li><li>SINA (NASDAQ:<a href='https://seekingalpha.com/symbol/SINA' title='SINA Corporation'>SINA</a>) <font color=\"red\">-9%</font> on <a href=\"https://seekingalpha.com/news/3519079-sina-eps-beats-0_22-beats-revenue\" target=\"_blank\">Q3 earnings</a>.</li><li>BioCryst Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/BCRX' title='BioCryst Pharmaceuticals, Inc.'>BCRX</a>) <font color=\"red\">-8%</font> on <a href=\"https://seekingalpha.com/news/3519208-biocryst-4-percent-premarket-pricing-equity-offering\" target=\"_blank\">pricing</a> equity offering.</li><li>Applied DNA Sciences (NASDAQ:<a href='https://seekingalpha.com/symbol/APDN' title='Applied DNA Sciences, Inc.'>APDN</a>) <font color=\"red\">-7%</font>.</li><li>Cisco Systems (NASDAQ:<a href='https://seekingalpha.com/symbol/CSCO' title='Cisco Systems, Inc.'>CSCO</a>) <font color=\"red\">-6%</font> on <a href=\"https://seekingalpha.com/news/3518915-cisco-minus-4_7-percent-q2-forecast-disappoints\" target=\"_blank\">Q1 earnings</a>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3519275\" data-linked=\"WB, CGC among premarket losers\" data-tweet=\"$VTGN $ROYT $IDEX - WB, CGC among premarket losers https://seekingalpha.com/news/3519275-wb-cgc-among-premarket-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3519275-wb-cgc-among-premarket-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:21 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3519264\" data-ts=\"1573740882\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SRPT\" target=\"_blank\">SRPT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3519264-sarepta-teams-up-stridebio-to-develop-up-to-eight-gene-therapies\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sarepta teams up with StrideBio to develop up to eight gene therapies</a></h4><ul><li>Sarepta Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/SRPT' title='Sarepta Therapeutics, Inc.'>SRPT</a>) will <a href=\"https://seekingalpha.com/pr/17699301-sarepta-stridebio-announce-multi-target-strategic-collaboration-advance-novel-gene-therapies\" target=\"_blank\">collaborate </a>with privately held <a href=\"https://www.stridebio.com/\" target=\"_blank\">StrideBio</a> to develop up to eight AAV-based gene therapies for central nervous system and neuromuscular disorders.</li><li>Under the terms of the agreement, StrideBio will receive $48M upfront in cash and SRPT common stock, milestones and royalties on net sales.</li><li>Sarepta will have an exclusive option to in-license up to four programs. It may secure an additional exclusive license for up to four additional targets by paying another upfront fee of $42.5M plus milestones and royalties and has agreed to invest in StrideBio's next financing round.</li><li>SrideBio has the option to co-develop and co-commercialize one target.</li><li>The companies will also investigate re-dosing strategies related to AAV-delivered gene therapy (restricted to single administration at present).</li><li>Shares down <font color=\"red\">1%</font> premarket.</li></ul><div class=\"tiny-share-widget\" data-id=\"3519264\" data-linked=\"Sarepta teams up with StrideBio to develop up to eight gene therapies\" data-tweet=\"$SRPT - Sarepta teams up with StrideBio to develop up to eight gene therapies https://seekingalpha.com/news/3519264-sarepta-teams-up-stridebio-to-develop-up-to-eight-gene-therapies?source=tweet\" data-url=\"https://seekingalpha.com/news/3519264-sarepta-teams-up-stridebio-to-develop-up-to-eight-gene-therapies\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:14 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3519262\" data-ts=\"1573740588\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3519262-sdrl-plug-among-premarket-gainers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">SDRL, PLUG among premarket gainers</a></h4><ul><li>Exicure (NASDAQ:<a href='https://seekingalpha.com/symbol/XCUR' title='Exicure, Inc.'>XCUR</a>) <font color=\"green\">+30%</font> on collaboration with Allergan in hair loss disorders.</li><li>Opera (NASDAQ:<a href='https://seekingalpha.com/symbol/OPRA' title='Opera Limited'>OPRA</a>) <font color=\"green\">+19%</font> after <a href=\"https://seekingalpha.com/news/3519136-opera-eps-beats-0_10-beats-revenue\" target=\"_blank\">Q3 results</a>.</li><li>Ping Identity Holding (NYSE:<a href='https://seekingalpha.com/symbol/PING' title='Ping Identity Holding Corp.'>PING</a>) <font color=\"green\">+19%</font> after <a href=\"https://seekingalpha.com/news/3518908-ping-identity-eps-beats-0_12-beats-revenue\" target=\"_blank\">Q3 results</a>.</li><li>Axonics Modulation Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/AXNX' title='Axonics Modulation Technologies, Inc.'>AXNX</a>) <font color=\"green\">+17%</font> as <a href=\"https://seekingalpha.com/news/3519184-fda-oks-axonics-snm-device-urinary-clinical-symptoms\" target=\"_blank\">FDA OKs</a> SNM device for urinary clinical symptoms.</li><li>TrovaGene (NASDAQ:<a href='https://seekingalpha.com/symbol/TROV' title='TrovaGene, Inc.'>TROV</a>) <font color=\"green\">+14%</font> on positive onvansertib <a href=\"https://seekingalpha.com/news/3519233-trovagene-17-percent-premarket-positive-onvansertib-data\" target=\"_blank\">data</a>.</li><li>Plug Power (NASDAQ:<a href='https://seekingalpha.com/symbol/PLUG' title='Plug Power Inc.'>PLUG</a>) <font color=\"green\">+7%</font>.</li><li>Seadrill (NYSE:<a href='https://seekingalpha.com/symbol/SDRL' title='Seadrill Limited'>SDRL</a>) <font color=\"green\">+6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3519262\" data-linked=\"SDRL, PLUG among premarket gainers\" data-tweet=\"$XCUR $OPRA $PING - SDRL, PLUG among premarket gainers https://seekingalpha.com/news/3519262-sdrl-plug-among-premarket-gainers?source=tweet\" data-url=\"https://seekingalpha.com/news/3519262-sdrl-plug-among-premarket-gainers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:09 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3519257\" data-ts=\"1573740260\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALT\" target=\"_blank\">ALT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3519257-altimmune-down-6-premarket-on-q3-miss\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Altimmune down 6% premarket on Q3 miss</a></h4><ul><li>Altimmune (<a href='https://seekingalpha.com/symbol/ALT' title='Altimmune, Inc.'>ALT</a>) <a href=\"https://seekingalpha.com/pr/17698459-altimmune-announces-third-quarter-2019-financial-results-provides-business-update\" target=\"_blank\">Q3 results</a>: Revenues: $0.6M (-76.9%).</li><li>Net loss: ($10.9M); loss/share: ($0.74) (+57.2%); Quick Assets: $11M (-67.4%).</li><li>Shares are down <font color=\"red\">6%</font> premarket.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3518945-altimmune-eps-misses-0_55-misses-revenue\" target=\"_blank\">Altimmune EPS misses by $0.55, misses on revenue</a> (Nov. 13)</li></ul><div class=\"tiny-share-widget\" data-id=\"3519257\" data-linked=\"Altimmune down 6% premarket on Q3 miss\" data-tweet=\"$ALT - Altimmune down 6% premarket on Q3 miss https://seekingalpha.com/news/3519257-altimmune-down-6-premarket-on-q3-miss?source=tweet\" data-url=\"https://seekingalpha.com/news/3519257-altimmune-down-6-premarket-on-q3-miss\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:04 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3519251\" data-ts=\"1573739994\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3519251-china-lifts-u-s-poultry-import-restrictions\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">China lifts U.S. poultry import restrictions</a></h4><ul> <li>Poultry stocks are on watch after Chinese officials <a href=\"https://www.reuters.com/article/us-usa-china-trade-poultry/china-lifts-restrictions-on-u-s-poultry-meat-imports-customs-idUSKBN1XO191\" target=\"_blank\">confirm</a> the government is lifting restrictions on importing U.S. poultry products. The decision was highly anticipated with China facing a gigantic protein shortage due to the impact of African Swine Fever on the local hog population.</li> <li>In premarket action, Tyson Foods (NYSE:<a href='https://seekingalpha.com/symbol/TSN' title='Tyson Foods, Inc.'>TSN</a>) is <font color=\"green\">up 1.55%</font> and Sanderson Farms (NASDAQ:<a href='https://seekingalpha.com/symbol/SAFM' title='Sanderson Farms, Inc.'>SAFM</a>) is <font color=\"green\">1.33% higher</font>. Pilgrim's Pride (NASDAQ:<a href='https://seekingalpha.com/symbol/PPC' title='Pilgrim&#39;s Pride Corporation'>PPC</a>) is showing a <font color=\"green\">0.38% gain</font> in the early session.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3519251\" data-linked=\"China lifts U.S. poultry import restrictions\" data-tweet=\"$TSN $SAFM $PPC - China lifts U.S. poultry import restrictions https://seekingalpha.com/news/3519251-china-lifts-u-s-poultry-import-restrictions?source=tweet\" data-url=\"https://seekingalpha.com/news/3519251-china-lifts-u-s-poultry-import-restrictions\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:59 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3519249\" data-ts=\"1573739921\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BCLI\" target=\"_blank\">BCLI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3519249-brainstorm-cell-down-6-premarket-on-q3-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BrainStorm Cell down 6% premarket on Q3 results</a></h4><ul><li>BrainStorm Cell Therapeutics (<a href='https://seekingalpha.com/symbol/BCLI' title='Brainstorm Cell Therapeutics Inc.'>BCLI</a>) <a href=\"https://seekingalpha.com/pr/17698851-brainstorm-announces-financial-results-third-quarter-2019-provides-corporate-update\" target=\"_blank\">Q3 results</a>: Revenues: $0; R&amp;D Expense: $4M (+100.0%); SG&amp;A: $1.5M (+15.4%); Net loss: ($5.6M) (-75.0%); loss/share: ($0.25) (-66.7%); Quick Assets: $2.1M (-70.4%).</li><li>Shares are down <font color=\"red\">6%</font> premarket.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3519091-brainstorm-cell-therapeutics-eps-misses-0_03\" target=\"_blank\">BrainStorm Cell Therapeutics EPS misses by $0.03</a> (Nov. 14)</li></ul><div class=\"tiny-share-widget\" data-id=\"3519249\" data-linked=\"BrainStorm Cell down 6% premarket on Q3 results\" data-tweet=\"$BCLI - BrainStorm Cell down 6% premarket on Q3 results https://seekingalpha.com/news/3519249-brainstorm-cell-down-6-premarket-on-q3-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3519249-brainstorm-cell-down-6-premarket-on-q3-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:58 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3519247\" data-ts=\"1573739804\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ARVN\" target=\"_blank\">ARVN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3519247-jpmorgan-likes-qiagen-in-premarket-analyst-action\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">JPMorgan likes Qiagen in premarket analyst action</a></h4><ul><li>Arvinas (NASDAQ:<a href='https://seekingalpha.com/symbol/ARVN' title='Arvinas, Inc.'>ARVN</a>) initiated with Buy rating and $35 (23% upside) price target at Roth Capital.</li><li>Bicycle Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/BCYC' title='Bicycle Therapeutics plc'>BCYC</a>) initiated with Buy rating and $17 (107% upside) at Roth.</li><li>Harpoon Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/HARP' title='Harpoon Therapeutics, Inc.'>HARP</a>) initiated with Buy rating and $25 (85% upside) price target at Roth.</li><li>Turning Point Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/TPTX' title='Turning Point Therapeutics, Inc.'>TPTX</a>) initiated with Buy rating and $65 (33% upside) price target at Roth.</li><li>VBI Vaccines (NASDAQ:<a href='https://seekingalpha.com/symbol/VBIV' title='VBI Vaccines Inc.'>VBIV</a>) initiated with Outperform rating and $3 (437% upside) price target at Raymond James. Shares up <font color=\"green\">10%</font> premarket.</li><li>Vir Biotechnology (NASDAQ:<a href='https://seekingalpha.com/symbol/VIR' title='Vir Biotechnology, Inc.'>VIR</a>) initiated with Neutral rating and $17 (31% upside) price target at Baird.</li><li>QIAGEN (NYSE:<a href='https://seekingalpha.com/symbol/QGEN' title='QIAGEN N.V.'>QGEN</a>) upgraded to Hold with a $36.31 (2% upside) price target at Kepler Cheuvreux. Upgraded to Overweight with a $40 price target at JPMorgan. Shares up <font color=\"green\">3%</font> premarket.</li><li>ElectroCore (NASDAQ:<a href='https://seekingalpha.com/symbol/ECOR' title='electroCore, Inc.'>ECOR</a>) downgraded to Market Perform at JMP Securities. Shares down <font color=\"red\">13%</font> after Q3 miss.</li></ul><div class=\"tiny-share-widget\" data-id=\"3519247\" data-linked=\"JPMorgan likes Qiagen in premarket analyst action\" data-tweet=\"$ARVN $BCYC $HARP - JPMorgan likes Qiagen in premarket analyst action https://seekingalpha.com/news/3519247-jpmorgan-likes-qiagen-in-premarket-analyst-action?source=tweet\" data-url=\"https://seekingalpha.com/news/3519247-jpmorgan-likes-qiagen-in-premarket-analyst-action\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:56 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3519233\" data-ts=\"1573738981\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TROV\" target=\"_blank\">TROV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3519233-trovagene-up-17-premarket-on-positive-onvansertib-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Trovagene up 17% premarket on positive onvansertib data</a></h4><ul><li>Nano cap Trovagene (NASDAQ:<a href='https://seekingalpha.com/symbol/TROV' title='TrovaGene, Inc.'>TROV</a>) is up <font color=\"green\">17%</font> premarket on increased volume in reaction to <a href=\"https://seekingalpha.com/pr/17699115-trovagene-presents-positive-data-metastatic-prostate-cancer-phase-2-trial-showing-clinical\" target=\"_blank\">encouraging data</a> from a <a href=\"https://clinicaltrials.gov/ct2/show/NCT03414034\" target=\"_blank\">Phase 2 clinical trial</a> evaluating onvansertib, combined with J&amp;J's Zytiga (abiraterone acetate) and prednisone, in patients with metastatic castration-resistant prostate cancer. The results are being presented today at the European Multidisciplinary Congress on Urological Cancers in Vienna.</li><li>The response rate was 60% (n=9/15) in patients that completed three months' treatment. 72% experienced a decline in PSA values after one cycle of treatment (number of patients not provided). Six patients have remained on treatment for at least four months.</li><li>On the safety front, the most frequent adverse events were anemia, neutropenia, thrombocytopenia and white blood cell decrease. All were managed by decreasing the dose of onvansertib or adding growth factor support.</li><li>The study should wind up in October 2020.</li></ul><div class=\"tiny-share-widget\" data-id=\"3519233\" data-linked=\"Trovagene up 17% premarket on positive onvansertib data\" data-tweet=\"$TROV - Trovagene up 17% premarket on positive onvansertib data https://seekingalpha.com/news/3519233-trovagene-up-17-premarket-on-positive-onvansertib-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3519233-trovagene-up-17-premarket-on-positive-onvansertib-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:43 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3519231\" data-ts=\"1573738953\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DDAIF\" target=\"_blank\">DDAIF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3519231-daimlerminus-3-after-profit-warning\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Daimler -3% after profit warning</a></h4><ul> <li>Shares of Daimler (<a href='https://seekingalpha.com/symbol/DDAIF' title='Daimler AG'>OTCPK:DDAIF</a>) stumble after the company <a href=\"https://www.wsj.com/articles/daimler-warns-on-profits-aims-to-cut-labor-costs-11573737629\" target=\"_blank\">warns</a> at an investor event in London on the costs to meet emission targets.</li> <li>\"The cost burdens to reach the targets on carbon-dioxide emissions require far-reaching measures to increase efficiency in every area of our company. This will weigh on our earnings in 2020 and 2021,\" stated Daimler CEO Ola Källenius.</li> <li>Daimler says it will cut more than 1K executive-level positions in an effort to lower costs.</li> <li>Daimler is <font color=\"red\">2.85% lower</font> in Frankfurt trading after being down more than 4% earlier in the session.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3519231\" data-linked=\"Daimler -3% after profit warning\" data-tweet=\"$DDAIF - Daimler -3% after profit warning https://seekingalpha.com/news/3519231-daimlerminus-3-after-profit-warning?source=tweet\" data-url=\"https://seekingalpha.com/news/3519231-daimlerminus-3-after-profit-warning\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:42 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3519227\" data-ts=\"1573738242\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BYND\" target=\"_blank\">BYND</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3519227-beyond-meatplus-2-after-attracting-new-bull-from-germany\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Beyond Meat +2% after attracting new bull from Germany</a></h4><ul> <li>Berenberg starts off coverage on Beyond Meat (NASDAQ:<a href='https://seekingalpha.com/symbol/BYND' title='Beyond Meat, Inc.'>BYND</a>) with a Buy rating.</li> <li>The German firm says even though some food heavyweights are entering the alternative protein space, Beyond Meat is the only pure-play stock in the rapidly growing category. Analyst Donald McLee points to the company's distribution and innovation advantages as well.</li> <li>Berenberg's price target of $100 reps ~25% upside potential for Beyond Meat.</li> <li>Wall Street is actually fairly cool on Beyond Meat, with only <a href=\"https://seekingalpha.com/symbol/BYND/ratings/sell-side-ratings?s=bynd\" target=\"_blank\">4 Buy-equivalent ratings</a> stacking up against 8 Neutral-equivalent ratings and 3 Sell-equivalent ratings. Seeking Alpha authors as a whole still have a <a href=\"https://seekingalpha.com/symbol/BYND/ratings/author-ratings#filter=all\" target=\"_blank\">bearish stance</a>.</li> <li>Shares of BYND are <font color=\"green\">up 2.38%</font> premarket to $80.89.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3519227\" data-linked=\"Beyond Meat +2% after attracting new bull from Germany\" data-tweet=\"$BYND - Beyond Meat +2% after attracting new bull from Germany https://seekingalpha.com/news/3519227-beyond-meatplus-2-after-attracting-new-bull-from-germany?source=tweet\" data-url=\"https://seekingalpha.com/news/3519227-beyond-meatplus-2-after-attracting-new-bull-from-germany\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:30 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>24&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3519225\" data-ts=\"1573737782\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TGP\" target=\"_blank\">TGP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3519225-teekay-companies-higher-after-earnings-bahrain-lng-to-start-year-end\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Teekay companies higher after earnings; Bahrain LNG to start by year-end</a></h4><ul><li>The Teekay trio of companies are all higher pre-market after issuing Q3 results following yesterday's close: <a href='https://seekingalpha.com/symbol/TGP' title='Teekay LNG Partners L.P.'>TGP</a> <font color=\"green\">+10%</font>, <a href='https://seekingalpha.com/symbol/TNK' title='Teekay Tankers Ltd.'>TNK</a> <font color=\"green\">+2.9%</font>, <a href='https://seekingalpha.com/symbol/TK' title='Teekay Corporation'>TK</a> <font color=\"green\">+1.8%</font>.</li><li>Teekay LNG Partners reported better than expected <a href=\"https://seekingalpha.com/news/3518920-teekay-lng-eps-beats-0_06-misses-revenue\" target=\"_blank\">Q3 earnings</a> and a 21% Y/Y rise in revenues to $149M; and said it expects distributions to increase by 32% to $1.00/year starting in Q1 2020, the second straight year of distribution growth in excess of 30%.</li><li>TGP raised FY 2019 earnings guidance by 11% at the midpoint, now seeing EPS of $1.75-$1.85 vs. $1.79 analyst consensus estimate; for FY 2020, it expects EPS of $2.60-$3.10 vs. $2.77 consensus.</li><li>TGP said the Bahrain LNG regasification terminal is now expected to  <a href=\"https://www.reuters.com/article/bahrain-lng-imports/bahrain-lng-terminal-to-start-operations-by-year-end-teekay-idUSL4N27U15D\" target=\"_blank\">start operations by year-end</a>, following some delays; TGP owns a 30% stake in the venture.</li><li>Teekay Tankers also showed better than forecast <a href=\"https://seekingalpha.com/news/3518932-teekay-tankers-eps-beats-0_03-misses-revenue\" target=\"_blank\">Q3 earnings</a> while revenues rose slightly; adjusted EBITDA of $27.8M was essentially flat Y/Y.</li><li>TNK said crude spot tanker rates began jumping in late September and into October to the highest levels since 2008, and Suezmax and Aframax tanker rates secured so far in Q4 have averaged 133% and 105% higher than in Q3.</li></ul><div class=\"tiny-share-widget\" data-id=\"3519225\" data-linked=\"Teekay companies higher after earnings; Bahrain LNG to start by year-end\" data-tweet=\"$TGP $TNK $TK - Teekay companies higher after earnings; Bahrain LNG to start by year-end https://seekingalpha.com/news/3519225-teekay-companies-higher-after-earnings-bahrain-lng-to-start-year-end?source=tweet\" data-url=\"https://seekingalpha.com/news/3519225-teekay-companies-higher-after-earnings-bahrain-lng-to-start-year-end\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:23 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>40&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3519221\" data-ts=\"1573737406\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MTOR\" target=\"_blank\">MTOR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3519221-meritor-gains-after-keybanc-lift\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Meritor gains after KeyBanc lift</a></h4><ul> <li>KeyBanc upgrades Meritor (NYSE:<a href='https://seekingalpha.com/symbol/MTOR' title='Meritor, Inc.'>MTOR</a>) to an Overweight rating from Sector Weight on its view the company will see strong EPS growth.</li> <li>The firm also thinks Meritor's balance sheet will be strong enough to support share buybacks.</li> <li>KeyBanc assigns a price target of $29 to Meritor to rep 22% upside potential. The average sell-side PT is <a href=\"https://seekingalpha.com/symbol/MTOR/ratings/sell-side-ratings\" target=\"_blank\">$25.29</a>.</li> <li>Shares of Meritor are <font color=\"green\">up 1.09%</font> premarket to $24.04.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3519221\" data-linked=\"Meritor gains after KeyBanc lift\" data-tweet=\"$MTOR - Meritor gains after KeyBanc lift https://seekingalpha.com/news/3519221-meritor-gains-after-keybanc-lift?source=tweet\" data-url=\"https://seekingalpha.com/news/3519221-meritor-gains-after-keybanc-lift\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:16 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3519214\" data-ts=\"1573737131\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KDMN\" target=\"_blank\">KDMN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3519214-kadmon-prices-equity-offering-shares-down-1-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Kadmon prices equity offering; shares down 1% premarket</a></h4><ul><li>Kadmon Holdings (NYSE:<a href='https://seekingalpha.com/symbol/KDMN' title='Kadmon Holdings, Inc.'>KDMN</a>) slips <font color=\"red\">1%</font> premarket on modest volume in reaction to its <a href=\"https://seekingalpha.com/pr/17698700-kadmon-announces-pricing-public-offering-common-stock\" target=\"_blank\">public offering</a> of 26M common shares at $3.40 per share. Underwriters' over-allotment is an additional 3.9M shares. Gross proceeds should be ~488.4M.</li><li>Closing date is November 18.</li><li>Yesterday's close was $3.56.</li></ul><div class=\"tiny-share-widget\" data-id=\"3519214\" data-linked=\"Kadmon prices equity offering; shares down 1% premarket\" data-tweet=\"$KDMN - Kadmon prices equity offering; shares down 1% premarket https://seekingalpha.com/news/3519214-kadmon-prices-equity-offering-shares-down-1-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3519214-kadmon-prices-equity-offering-shares-down-1-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:12 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3519211\" data-ts=\"1573737087\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EMR\" target=\"_blank\">EMR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3519211-emerson-downgraded-to-reduce-hsbc\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Emerson downgraded to Reduce at HSBC</a></h4><ul><li>HSBC analyst Puneet Garg has downgraded Emerson Electric (NYSE:<a href='https://seekingalpha.com/symbol/EMR' title='Emerson Electric Co.'>EMR</a>) to Reduce from Hold.</li><li>A price target of $64 was set, implying 13% downside from yesterday's closing price.</li><li><a href='https://seekingalpha.com/symbol/EMR' title='Emerson Electric Co.'>EMR</a> <font color=\"red\">-1.7%</font> premarket</li><li>Source: Bloomberg First Word</li></ul><div class=\"tiny-share-widget\" data-id=\"3519211\" data-linked=\"Emerson downgraded to Reduce at HSBC\" data-tweet=\"$EMR - Emerson downgraded to Reduce at HSBC https://seekingalpha.com/news/3519211-emerson-downgraded-to-reduce-hsbc?source=tweet\" data-url=\"https://seekingalpha.com/news/3519211-emerson-downgraded-to-reduce-hsbc\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:11 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3519208\" data-ts=\"1573736929\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BCRX\" target=\"_blank\">BCRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3519208-biocryst-down-4-premarket-after-pricing-equity-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BioCryst down 4% premarket after pricing equity offering</a></h4><ul><li>BioCryst Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/BCRX' title='BioCryst Pharmaceuticals, Inc.'>BCRX</a>) slips <font color=\"red\">4%</font> premarket on average volume in reaction to its <a href=\"https://seekingalpha.com/pr/17698678-biocryst-prices-public-offering-common-stock\" target=\"_blank\">public offering</a> of ~37.9M common shares at $1.45 per share. Underwriters' over-allotment is an additional ~5.7M shares.</li><li>Gross proceeds should be ~$55M. Closing date is November 18.</li><li>Yesterday's close was $1.60.</li></ul><div class=\"tiny-share-widget\" data-id=\"3519208\" data-linked=\"BioCryst down 4% premarket after pricing equity offering\" data-tweet=\"$BCRX - BioCryst down 4% premarket after pricing equity offering https://seekingalpha.com/news/3519208-biocryst-down-4-premarket-after-pricing-equity-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3519208-biocryst-down-4-premarket-after-pricing-equity-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:08 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3519203\" data-ts=\"1573736724\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HALO\" target=\"_blank\">HALO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3519203-halozyme-prices-convertible-debt-offering-shares-ahead-2-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Halozyme prices convertible debt offering; shares ahead 2% premarket</a></h4><ul><li>Halozyme (NASDAQ:<a href='https://seekingalpha.com/symbol/HALO' title='Halozyme Therapeutics, Inc.'>HALO</a>) prices its <a href=\"https://seekingalpha.com/pr/17698709-halozyme-therapeutics-inc-announces-pricing-private-offering-400-million-convertible-senior\" target=\"_blank\">private offering</a> of $400M of 1.25% Convertible Senior Notes due 2024 at par. The initial conversion rate is 41.9208 (~$23.85/common share).</li><li>Net proceeds should be ~$388.5M. Closing date is November 18.</li><li>Initial purchasers will have an option to buy up to an additional $60M of the Notes.</li><li>~$200M of net proceeds will fund stock buybacks. $26.1M will be used to repay its outstanding loan from Oxford Finance and Silicon Valley Bank.</li><li>Shares up <font color=\"green\">2%</font> premarket on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3519203\" data-linked=\"Halozyme prices convertible debt offering; shares ahead 2% premarket\" data-tweet=\"$HALO - Halozyme prices convertible debt offering; shares ahead 2% premarket https://seekingalpha.com/news/3519203-halozyme-prices-convertible-debt-offering-shares-ahead-2-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3519203-halozyme-prices-convertible-debt-offering-shares-ahead-2-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:05 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3519192\" data-ts=\"1573736406\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DE\" target=\"_blank\">DE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3519192-bofa-returns-deere-to-neutral\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BofA returns Deere to &#39;Neutral&#39;</a></h4><ul><li>Deere (NYSE:<a href='https://seekingalpha.com/symbol/DE' title='Deere & Company'>DE</a>) <font color=\"red\">-1%</font> premarket after BofA-Merrill Lynch cut its recommendation on the stock to Neutral from Buy, and set a PT of $175, implying 0.4% downside from yesterday's close.</li><li>BofA last downgraded Deere to Neutral in January after an impressive run, but then raised shares back to Buy in July, citing what it said are limited chances of a global recession in the near term.</li></ul><div class=\"tiny-share-widget\" data-id=\"3519192\" data-linked=\"BofA returns Deere to &#39;Neutral&#39;\" data-tweet=\"$DE - BofA returns Deere to &#39;Neutral&#39; https://seekingalpha.com/news/3519192-bofa-returns-deere-to-neutral?source=tweet\" data-url=\"https://seekingalpha.com/news/3519192-bofa-returns-deere-to-neutral\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:00 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3519191\" data-ts=\"1573736364\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FLGT\" target=\"_blank\">FLGT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3519191-fulgent-down-12-premarket-after-pricing-equity-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Fulgent down 12% premarket after pricing equity offering</a></h4><ul><li>Thinly traded micro cap Fulgent Genetics (NASDAQ:<a href='https://seekingalpha.com/symbol/FLGT' title='Fulgent Genetics, Inc.'>FLGT</a>) is down <font color=\"red\">12% </font>premarket on modest volume in reaction to its <a href=\"https://seekingalpha.com/pr/17698710-fulgent-genetics-announces-pricing-public-offering-common-stock\" target=\"_blank\">public offering</a> of ~2.3M common shares at $11.25 per share.</li><li>Underwriters' over-allotment is an additional ~349K shares. Closing date is November 18.</li><li>Gross proceeds should be ~$26.2M.</li><li>Yesterday's close was $13.64.</li></ul><div class=\"tiny-share-widget\" data-id=\"3519191\" data-linked=\"Fulgent down 12% premarket after pricing equity offering\" data-tweet=\"$FLGT - Fulgent down 12% premarket after pricing equity offering https://seekingalpha.com/news/3519191-fulgent-down-12-premarket-after-pricing-equity-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3519191-fulgent-down-12-premarket-after-pricing-equity-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:59 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3519189\" data-ts=\"1573736120\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AVXL\" target=\"_blank\">AVXL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3519189-fda-grants-rpd-status-to-anavex-2minus-73-shares-ahead-7-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA grants RPD status to Anavex 2-73; shares ahead 7% premarket</a></h4><ul><li>The FDA <a href=\"https://seekingalpha.com/pr/17698953-anavex-life-sciences-receives-rare-pediatric-disease-designation-fda-anavex-2minus-73\" target=\"_blank\">grants </a>Rare Pediatric Disease &#40;RPD&#41; designation to Anavex Life Sciences' (NASDAQ:<a href='https://seekingalpha.com/symbol/AVXL' title='Anavex Life Sciences Corp.'>AVXL</a>) lead drug Anavex 2-73 (blarcamesine) for the treatment of a rare inherited neurological disorder called <a href=\"https://www.rettsyndrome.org/\" target=\"_blank\">Rett syndrome</a> that affects mostly girls.</li><li>RPD Designation provides for the issuance of a rare pediatric disease priority review voucher following FDA approval. The voucher can be used for accelerated approval of a future application or it can be sold to a third party.</li><li>Phase 2 studies are in process.</li><li>Shares up <font color=\"green\">7%</font> premarket on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3519189\" data-linked=\"FDA grants RPD status to Anavex 2-73; shares ahead 7% premarket\" data-tweet=\"$AVXL - FDA grants RPD status to Anavex 2-73; shares ahead 7% premarket https://seekingalpha.com/news/3519189-fda-grants-rpd-status-to-anavex-2minus-73-shares-ahead-7-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3519189-fda-grants-rpd-status-to-anavex-2minus-73-shares-ahead-7-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:55 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":75,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}